🏷

Classifications

Harrison's Part

👪

Inheritance

1

X-linked inheritance, typically de novo HP:0001417

MICPCH is inherited in an X-linked manner. Almost all affected individuals are simplex cases resulting from a de novo CASK loss-of-function variant. Because heterozygous females manifest the phenotype, an asymptomatic mother is unlikely to be a heterozygote, which is the key counselling point. Hemizygous males with a true loss-of-function allele have a severe-to-profound phenotype with early, often intractable epilepsy; the small number of more mildly affected males carry the variant in the mosaic state or carry a hypomorphic allele.

X-linked inheritance Expressivity: VARIABLE

Show evidence (3 references)

PMID:24278995 SUPPORT Human Clinical

"CASK disorders are inherited in an X-linked manner."

GeneReviews states the mode of inheritance.

PMID:24278995 SUPPORT Human Clinical

"Most affected females and males represent simplex cases (i.e., the only affected family member) and have the disorder as the result of a de novo CASK pathogenic variant. Because heterozygous females manifest the phenotype, an asymptomatic mother is unlikely to be heterozygous for the CASK..."

Establishes the predominance of de novo variants and the counselling implication that asymptomatic mothers are unlikely to be carriers.

PMID:22452838 SUPPORT Human Clinical

"As expected in an X-linked disease manifesting mainly in females, the boy hemizygous for a splice mutation had a very severe phenotype with nearly no development and refractory epilepsy. We described a mild phenotype in a boy with a mosaic truncating mutation."

Demonstrates the sex-dependent severity gradient and the ameliorating effect of somatic mosaicism in males.

?

Discussions and Knowledge Gaps

1

Which of CASK's several molecular functions actually accounts for the MICPCH brain phenotype, and does the relationship between CASK molecular function and tissue pathology in model organisms translate to human disease?

HUMAN MODEL MISMATCH OPEN micpch_cask_molecular_function_mapping

Attached to

pathophysiology#Disrupted CASK-Neurexin Presynaptic Scaffold Interaction pathophysiology#Disrupted CASK-Liprin-alpha2 Interaction via the CaMK Domain

CASK is a multidomain scaffold with many binding partners, and the literature has successively implicated the CASK-TBR1 transcriptional interface, the CASK-neurexin presynaptic interface and the CASK-Liprin-alpha2 interface. The investigators who built and characterised the MICPCH mouse models explicitly warn that the relationship between CASK molecular function and the phenotypes observed in model organisms and humans is highly complex and should not be oversimplified. The two molecular nodes curated here are therefore both retained rather than collapsed, and neither is asserted as the sole mechanism. Resolving this matters because a mechanism-directed therapy has to target the right interface.

Proposed experiments

Interface-specific Cask knock-in mouse allelic series

micpch_interface_specific_knockin

Generate mice carrying separation-of-function Cask alleles that independently disrupt the neurexin, Liprin-alpha2 and TBR1 interfaces, and compare cerebellar granule cell survival, cerebellar volume and behaviour.

Decision criterion

If only one interface allele reproduces cerebellar hypoplasia, that interface is the causal one; if several do, the mechanism is combinatorial.

Patient-derived cerebellar organoid interface rescue

micpch_patient_organoid_interface

Rescue CASK-null human cerebellar organoids with CASK constructs selectively defective for each interface and measure granule cell survival.

Decision criterion

Failure of a given construct to rescue identifies its interface as required in human tissue, addressing the model-to-human translation gap directly.

Show evidence (2 references)

PMID:35406695 SUPPORT Other

"Our studies point to a highly complex relationship between the potential molecular function/s of CASK and the phenotypes observed in model organisms and humans."

Expert perspective from the authors of the MICPCH mouse work, explicitly cautioning against a simple molecular-function-to-phenotype mapping; this is the substance of the open question, and is tagged OTHER because the source is a review rather than primary data.

PMID:35406695 SUPPORT Other

"Here we discuss the implications of our observations from the pathogenesis of MICPCH as a cautionary narrative against oversimplifying molecular interpretations of data obtained from genetically modified animal models of human diseases."

Framing sentence of a review stating the translational-validity caveat that motivates classifying this as HUMAN_MODEL_MISMATCH; curated as PARTIAL/OTHER because it declares a position rather than reporting a result.

⚙

Pathophysiology

10

CASK Loss of Function

Heterozygous (female) or hemizygous (male) null alleles of CASK at Xp11.4 - whole- and partial-gene deletions, intragenic duplications, nonsense, frameshift and splice variants - abolish CASK protein. In fibroblasts from individuals with a CASK loss-of-function variant no CASK protein is detectable, whereas mosaic or hypomorphic alleles leave residual protein, which is the molecular basis of the MICPCH-versus-XLID split. A minority of MICPCH-causing alleles are missense variants that destroy a specific protein-protein interface rather than the whole protein.

CASK hgnc:1497

protein-macromolecule adaptor activity GO:0030674 ↓ DECREASED

Downstream

Disrupted CASK-Neurexin Presynaptic Scaffold Interaction Loss of CASK removes the PDZ-domain-mediated link to presynaptic neurexins.

Disrupted CASK-Liprin-alpha2 Interaction via the CaMK Domain Loss of CASK removes the CaMK-domain-mediated link to Liprin-alpha2 that cerebellar granule cell survival depends on.

X-Linked Mosaicism and Competitive Cerebellar Cell Loss In heterozygous females, random X-inactivation creates a mosaic of CASK-positive and CASK-negative neurons that then compete.

Splice-Dependent Regional Specialisation of CASK Function Which CASK functions are lost depends on which alternatively spliced exons the variant affects, which is why the cerebellar and forebrain phenotypes can be genetically separated.

Excitatory-Inhibitory Synaptic Imbalance via GluN2B Downregulation Loss of CASK downregulates the NMDA receptor subunit GluN2B and shifts the excitatory/inhibitory balance. This edge is deliberately parented on the gene-level lesion rather than on the neurexin interface: the GluN2B effect has been attributed to CASK's nuclear/TBR1-cooperative role, which is a different interface from the presynaptic neurexin one, and the responsible interface is an open question recorded in `discussions`.

Show evidence (2 references)

PMID:21954287 SUPPORT Human Clinical

"11 submicroscopic copy number alterations, including nine deletions of ~11 kb to 4.5 Mb and two duplications, all covering (part of) CASK, four splice, four nonsense, and one 1 bp deletion are reported. These heterozygous CASK mutations most likely lead to a null allele."

Documents the loss-of-function variant spectrum and establishes that these alleles are functionally null.

PMID:25886057 SUPPORT In Vitro

"In fibroblasts from patients with a CASK loss-of-function mutation, no CASK protein could be detected. Individuals who are mosaic for a severe CASK mutation or carry a hypomorphic mutation still showed detectable amount of protein."

Direct protein-level demonstration that MICPCH alleles are null while mosaic/hypomorphic alleles retain protein, explaining the phenotypic split.

Disrupted CASK-Neurexin Presynaptic Scaffold Interaction

CASK binds the cytoplasmic tail of presynaptic neurexins through its PDZ domain, coupling the presynaptic adhesion machinery to the intracellular scaffold. Two MICPCH-causing missense variants in heterozygous girls (p.Met519Thr in the PDZ domain, p.Gly659Asp in the SH3 domain) each abolish neurexin binding while other aggregation-inducing CASK variants that leave the interaction intact do not cause MICPCH. This dissociates the neurexin interface from the previously assumed CASK-TBR1 transcriptional interface as the critical one for microcephaly and cerebellar hypoplasia.

synapse organization GO:0050808 ↓ DECREASED

Downstream

Impaired Cortical Excitatory Synaptic Maturation and Network Activity Loss of the presynaptic CASK-neurexin scaffold degrades synaptic transmission in cortical excitatory neurons.

Postnatal Brain Growth Failure and Progressive Microcephaly Variants that specifically disrupt the CASK-neurexin interface are sufficient to produce microcephaly and hindbrain hypoplasia in humans.

Show evidence (2 references)

PMID:29426960 SUPPORT In Vitro

"The mutation M519T results in the replacement of an evolutionarily invariant methionine located in the PDZ signaling domain known to be critical for the CASK-neurexin interaction. CASKM519T is incapable of binding to neurexin, suggesting a critically important role for the CASK-neurexin interaction."

Direct biochemical demonstration that a MICPCH-causing missense variant abolishes neurexin binding.

PMID:29426960 SUPPORT In Vitro

"Our results suggest that disruption of the CASK-neurexin interaction, not the CASK-Tbr-1 interaction, produces microcephaly and cerebellar hypoplasia."

Identifies the neurexin interface rather than the TBR1 interface as the critical one for the MICPCH brain phenotype.

Disrupted CASK-Liprin-alpha2 Interaction via the CaMK Domain

Rescue mapping in CASK-knockout cerebellar granule cells shows that the CaMK, PDZ and SH3 domains - but not the L27 or guanylate kinase domains - are required for granule cell survival. Patient-derived missense variants in the CaMK domain fail to rescue granule cell death, and structural prediction places them at the Liprin-alpha2 binding interface, implicating loss of the CASK-Liprin-alpha2 interaction as the proximate cause of granule cell death.

protein-macromolecule adaptor activity GO:0030674 ↓ DECREASED

Downstream

Cerebellar Granule Cell Apoptosis via JNK/ROS Signalling Loss of the CaMK-domain-mediated Liprin-alpha2 interaction removes the survival signal for cerebellar granule cells.

Show evidence (2 references)

PMID:37190086 SUPPORT In Vitro

"Rescue experiments with CASK deletion mutants identify that the CaMK, PDZ, and SH3, but not L27 and guanylate kinase domains of CASK are required for the survival of CG cells."

Domain-mapping rescue experiments localise the granule-cell survival function to specific CASK domains.

PMID:37190086 SUPPORT Computational

"Machine learning-based structural analysis using AlphaFold 2.2 predicts that these mutations disrupt the structure of the binding interface with Liprin-α2."

The Liprin-alpha2 interface assignment rests on AlphaFold structural prediction rather than direct structure determination, so this is curated as partial computational support.

Cerebellar Granule Cell Apoptosis via JNK/ROS Signalling

CASK-knockout cerebellar granule cells undergo progressive apoptosis with activation of intracellular Jun N-terminal kinase signalling and upregulation of reactive-oxygen-species-related gene expression. Pharmacological JNK inhibition with JNK-IN-8 increases granule cell survival in vitro by reducing ROS generation, and intracerebellar injection suppresses granule cell death and alleviates ataxic behaviour in heterozygous CASK-knockout mice, making this the first tractable therapeutic node in the disorder. This granule-cell death mechanism is the reason the entry does not conform to the Purkinje-centred cerebellar degeneration module.

cerebellar granule cell CL:0001031

apoptotic process GO:0006915 ↑ INCREASED cerebellar granular layer morphogenesis GO:0021683 ⚠ ABNORMAL

Downstream

Progressive Pontine and Cerebellar Hypoplasia Cumulative granule cell loss produces the progressive cerebellar hypoplasia seen on serial imaging.

Show evidence (3 references)

PMID:40422253 SUPPORT In Vitro

"We performed RNA-sequencing (RNA-seq) on these cells and found that CASK-KO CG cells underwent apoptosis by activating intracellular Jun N-terminal kinase (JNK) signaling and upregulating reactive oxygen species (ROS)-related gene expression."

Identifies JNK activation and ROS upregulation as the apoptotic pathway in CASK-deficient cerebellar granule cells.

PMID:40422253 SUPPORT Model Organism

"injection of JNK-IN-8 into the cerebellum of CASK+/- HprteGFP/+ mice suppressed CG cell death and alleviated cerebellar ataxic phenotypes in vivo"

In vivo rescue of granule cell death and ataxia by JNK inhibition, establishing this node as causally upstream of the cerebellar phenotype and as a therapeutic target.

PMID:37190086 SUPPORT In Vitro

"CASK KO cultured cerebellar granule (CG) cells show progressive cell death that can be rescued by co-infection with lentivirus expressing wild-type CASK."

Establishes that granule cell death is cell-autonomously caused by CASK loss and is reversible by CASK restoration.

X-Linked Mosaicism and Competitive Cerebellar Cell Loss

Because CASK is subject to X-chromosome inactivation, heterozygous females carry a mosaic of CASK-expressing and CASK-deficient neurons. In the female heterozygous knockout mouse, roughly half of cerebellar granule cells are CASK-negative during early postnatal development, yet almost all surviving granule and Purkinje cells are CASK-positive in adulthood - the CASK-negative population is selectively eliminated. Comparison with hypomorphic mice indicates the survival of granule cells is set by a combination of cell-autonomous and cell-competitive mechanisms. This explains why the female phenotype is severe rather than mitigated by mosaicism, and why total cell number, not just cell function, is reduced.

cerebellar granule cell CL:0001031 Purkinje cell CL:0000121

Downstream

Progressive Pontine and Cerebellar Hypoplasia Selective elimination of the CASK-deficient neuronal population reduces cerebellar cell number and cortical thickness.

Show evidence (2 references)

PMID:40422238 SUPPORT Model Organism

"although half of the cerebellar granule cells were CASK-negative during early postnatal development, almost all Purkinje cells and cerebellar granule cells were CASK-positive in adulthood, suggesting that CASK expression may determine the survival of cerebellar granule cells during postnatal development"

Demonstrates selective postnatal elimination of the CASK-negative neuronal population in the mosaic female brain.

PMID:40422238 SUPPORT Other

"The CASK gene is regulated by X-chromosome inactivation, which results in a mosaic distribution of CASK-expressing and CASK-deficient neurons in the female brain."

Background statement of the X-inactivation mosaicism premise (about the human female brain, not the mouse result); tagged OTHER because it is framing rather than data. The experimental finding is carried by the preceding item.

Impaired Cortical Excitatory Synaptic Maturation and Network Activity

In isogenic human embryonic stem cell-derived cortical excitatory induced neurons, CASK knockout leaves immature neuronal outgrowth, synapse number and neuronal morphology intact but produces severe defects in synaptic transmission and in synchronised network activity as the neurons mature. CASK therefore acts on the functional maturation of cortical excitatory networks rather than on their gross structural assembly, which is consistent with the clinical picture of profound cognitive and language impairment out of proportion to any cortical malformation.

cerebral cortex neuron CL:0010012

synapse assembly GO:0007416 ⚠ ABNORMAL

Downstream

Intellectual Disability Degraded excitatory network function underlies the cognitive impairment.

Absent or Severely Limited Speech The same cortical network deficit underlies the near-absent expressive language.

Show evidence (2 references)

PMID:36262316 SUPPORT In Vitro

"While immature CASK KO iNs show robust neuronal outgrowth, mature CASK KO iNs display severe defects in synaptic transmission and synchronized network activity without compromising neuronal morphology and synapse numbers."

Isogenic human neuron model shows the deficit is in synaptic function and network synchrony rather than in neuronal morphology or synapse number.

PMID:36262316 SUPPORT In Vitro

"In the developing human cortical excitatory neurons, CASK functions to promote both structural integrity and establishment of cortical excitatory neuronal networks."

Summarises CASK's role in establishing human cortical excitatory networks. The wording about structural integrity refers to CASK's role across development generally; in this specific isogenic assay the mature-neuron deficit was functional (transmission and network synchrony) with morphology and synapse number preserved, as stated in the node description.

Excitatory-Inhibitory Synaptic Imbalance via GluN2B Downregulation

Exploiting X-chromosome inactivation in heterozygous female CASK-knockout mice, CASK-deficient and CASK-expressing neurons can be compared side by side in the same slice. Both CASK-knockout and CASK-knockdown neurons show a disrupted excitatory/inhibitory balance, the NMDA receptor subunit GluN2B is downregulated, and overexpressing GluN2B rescues the imbalance - identifying GluN2B loss as a mediator. This is a distinct, postsynaptic-facing arm of the mechanism from the presynaptic CASK-neurexin scaffold arm, and it provides a plausible substrate for the epilepsy seen in roughly half of individuals.

cerebral cortex neuron CL:0010012

synapse organization GO:0050808 ⚠ ABNORMAL

Downstream

Seizures A shifted excitatory/inhibitory balance is a plausible substrate for the epilepsy, though this link has been demonstrated in mouse rather than human tissue.

Show evidence (2 references)

PMID:30610199 SUPPORT Model Organism

"Both CASK-KO and CASK-KD neurons showed a disruption of the excitatory and inhibitory (E/I) balance."

Establishes disrupted excitatory/inhibitory balance as a direct consequence of CASK loss in mouse cortical neurons.

PMID:30610199 SUPPORT Model Organism

"We further found that the expression level of the N-methyl-D-aspartate receptor subunit GluN2B was decreased in CASK-KD neurons and that overexpressing GluN2B rescued the disrupted E/I balance in CASK-KD neurons."

Identifies GluN2B downregulation as the mediator, with rescue by GluN2B overexpression establishing causality within the model.

Splice-Dependent Regional Specialisation of CASK Function

Two vertebrate-specific CASK exons in the central part of the protein are alternatively spliced differently in forebrain and hindbrain, and their inclusion alters the structure of the CASK C-terminus. Damaging hemizygous variants clustered in exactly these exons produce boys with microcephaly and cerebral dysfunction but WITHOUT pontocerebellar hypoplasia. This is a third genotype class alongside the null (MICPCH) and hypomorphic (XLID) alleles, and it explains how the cerebellar and forebrain consequences of CASK loss can be genetically separated. It also implies an ongoing, non-developmental cerebellar requirement, since deleting Cask in adult mice causes cerebellar degeneration.

CASK hgnc:1497

Downstream

Cerebellar Granule Cell Apoptosis via JNK/ROS Signalling Loss of CASK function disproportionately affects the cerebellum, and the granule cell population is the demonstrated site of that vulnerability.

Show evidence (3 references)

PMID:38670634 SUPPORT Human Clinical

"Intriguingly, damaging hemizygous CASK mutations in boys who display microcephaly and cerebral dysfunction but without PCH are known. These mutations are present in two vertebrate-specific CASK exons."

Human genetic evidence that variants in two specific vertebrate-specific exons uncouple microcephaly from pontocerebellar hypoplasia.

PMID:38670634 SUPPORT Other

"These exons are subject to alternative splicing both in forebrain and hindbrain. Inclusion of these exons differentially affects the molecular structure and hence possibly the function/s of the CASK C-terminus."

RT-PCR and in silico structural analysis showing region-differential splicing of these exons and its structural consequence; tagged OTHER because it combines molecular-biology and computational structural evidence.

PMID:38670634 SUPPORT Model Organism

"Loss of CASK function disproportionately affects the cerebellum."

States the regional selectivity of CASK loss that this node captures.

Progressive Pontine and Cerebellar Hypoplasia

The neuroimaging hallmark is diffuse brainstem and cerebellar hypoplasia with a dilated fourth ventricle, of markedly varying degree. Quantitative morphometry distinguishes it from other pontocerebellar hypoplasias: the pons, midbrain, cerebellar vermis and hemispheres and the cerebrum are all reduced, but the corpus callosum is of normal size, giving a low cerebrum/corpus callosum ratio - the opposite of the pattern in other causes of pontine hypoplasia. Vermis hypoplasia severity correlates with clinical severity. Whether the cerebellar hypoplasia is truly progressive in humans is unsettled: the female heterozygous mouse shows progressive cerebellar hypoplasia and post-adult conditional deletion causes cerebellar degeneration and ataxia over time, but the human microcephaly with PCH has also been characterised as self-limiting, so this entry does not assert human progression.

cerebellum development GO:0021549 ⚠ ABNORMAL

cerebellum UBERON:0002037 pons UBERON:0000988

Downstream

Pontocerebellar Hypoplasia The tissue-level lesion is the imaging phenotype.

Postnatal Brain Growth Failure and Progressive Microcephaly Hindbrain volume loss contributes to the overall reduction in brain growth.

Show evidence (3 references)

PMID:21954287 SUPPORT Human Clinical

"Brain imaging consistently showed diffuse brainstem and cerebellar hypoplasia with a dilated fourth ventricle, but of remarkably varying degrees."

Establishes the consistent but variable brainstem-cerebellar imaging phenotype across a 25-patient series.

PMID:20595373 SUPPORT Human Clinical

"MR imaging in patients with CASK mutations revealed a normal size of the corpus callosum and a low ratio of the cerebrum/corpus callosum with a reduced area of the cerebrum, pons, midbrain, and cerebellar vermis and hemispheres."

Quantitative morphometry defining the CASK-specific imaging signature and distinguishing it from other pontine hypoplasias.

PMID:22452838 SUPPORT Human Clinical

"We found some degree of correlation between severity of the vermis hypoplasia and clinical phenotype."

Links the degree of vermis hypoplasia to clinical severity.

Postnatal Brain Growth Failure and Progressive Microcephaly

Head growth decelerates rather than being congenitally arrested, producing progressive postnatal microcephaly. Prenatal imaging shows this process can begin in utero: progressive deceleration of fetal head circumference growth rate was seen in 15 of 19 fetuses with available data, with a subset already below -2 SD and some with a small transcerebellar diameter, although most cases would not be picked up by current routine fetal CNS assessment.

Downstream

Progressive Microcephaly The organism-level growth failure is the clinical microcephaly.

Growth Retardation Somatic growth restriction frequently accompanies the head-growth failure.

Show evidence (2 references)

PMID:21954287 SUPPORT Human Clinical

"severe developmental delay/intellectual disability, severe postnatal microcephaly, often associated with growth retardation"

Establishes microcephaly as postnatal in onset and frequently accompanied by somatic growth retardation.

PMID:36175354 SUPPORT Human Clinical

"Progressive prenatal deceleration of head circumference growth rate was observed in 15 out of 19."

Shows that the head-growth deceleration begins prenatally in most fetuses in whom serial measurements were available.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

27

Digestive 1

Feeding Difficulties FREQUENT HP:0011968

Show evidence (2 references)

PMID:35670295 SUPPORT Human Clinical

"Additional findings, present in about one-third of individuals, include feeding difficulties, ophthalmologic issues, hypertonicity, epilepsy, and sensorineural hearing loss."

Quantifies feeding difficulties at about one-third of individuals, within the FREQUENT (30-79%) band.

PMID:33640666 SUPPORT Human Clinical

"feeding difficulties were more frequent in patients with epilepsy"

Links feeding difficulties to the presence of epilepsy within the cohort.

Ear 2

Sensorineural Hearing Loss FREQUENT Sensorineural hearing impairment HP:0000407

Show evidence (2 references)

PMID:24278995 SUPPORT Human Clinical

"MICPCH is typically seen in females with moderate-to-severe intellectual disability, progressive microcephaly with or without ophthalmologic anomalies, and sensorineural hearing loss."

GeneReviews includes sensorineural hearing loss in the typical MICPCH presentation.

PMID:41039189 SUPPORT Human Clinical

"we found consistent prevalence of tone abnormalities, sensorineural hearing loss and epilepsy"

Confirms that sensorineural hearing loss prevalence is consistent between historical and recently diagnosed cohorts. Caveat - this cohort spans the whole CASK-related spectrum, in which MICPCH was less prevalent than in the historical literature, so the figure is not MICPCH-specific.

Large Ears OCCASIONAL Macrotia HP:0000400

Show evidence (1 reference)

PMID:21954287 SUPPORT Human Clinical

"long philtrum, small chin, and/or large ears"

Large ears are listed as an optional ("and/or") component of the gestalt, supporting a conservative OCCASIONAL band.

Eye 1

Optic Atrophy OCCASIONAL HP:0000648

Show evidence (2 references)

PMID:22452838 SUPPORT Human Clinical

"ophthalmologic anomalies (glaucoma, megalocornea and optic atrophy)"

Lists optic atrophy among the ophthalmological anomalies frequently associated in this series.

PMID:41039189 SUPPORT Human Clinical

"we found consistent prevalence of tone abnormalities, sensorineural hearing loss and epilepsy, but lower prevalence of severe/profound ID, MICPCH, optic atrophy and nystagmus"

A recently diagnosed cohort found a lower prevalence of optic atrophy than earlier literature, which is why the band is set conservatively at OCCASIONAL. Caveat - this cohort spans the whole CASK-related spectrum, in which MICPCH was less prevalent than in the historical literature, so the figure is not MICPCH-specific.

Head and Neck 2

Long Philtrum FREQUENT HP:0000343

Show evidence (1 reference)

PMID:21954287 SUPPORT Human Clinical

"A recognisable facial phenotype emerged, including prominent and broad nasal bridge and tip, small or short nose, long philtrum, small chin, and/or large ears."

Long philtrum is listed as a component of the recognisable facial gestalt.

Micrognathia FREQUENT HP:0000347

Show evidence (1 reference)

PMID:21954287 SUPPORT Human Clinical

"A recognisable facial phenotype emerged, including prominent and broad nasal bridge and tip, small or short nose, long philtrum, small chin, and/or large ears."

A small chin is listed as a component of the recognisable facial gestalt.

Musculoskeletal 2

Spasticity of the Extremities FREQUENT HP:0001257

Show evidence (2 references)

PMID:24278995 SUPPORT Human Clinical

"Neurologic features may include axial hypotonia, hypertonia/spasticity of the extremities, and dystonia or other movement disorders."

GeneReviews lists hypertonia/spasticity of the extremities among the neurological features.

PMID:35670295 SUPPORT Human Clinical

"Additional findings, present in about one-third of individuals, include feeding difficulties, ophthalmologic issues, hypertonicity, epilepsy, and sensorineural hearing loss."

Quantifies hypertonicity at about one-third of individuals, within the FREQUENT (30-79%) band.

Scoliosis FREQUENT HP:0002650

Show evidence (1 reference)

PMID:22452838 SUPPORT Human Clinical

"characterized by psychomotor retardation, severe intellectual disability, progressive microcephaly, dystonia, mild dysmorphism, and scoliosis"

Scoliosis was among the features characterising the 11 girls of this series.

Nervous System 10

Intellectual Disability VERY_FREQUENT HP:0001249

Severity: SEVERE

Show evidence (2 references)

PMID:24278995 SUPPORT Human Clinical

"MICPCH is typically seen in females with moderate-to-severe intellectual disability, progressive microcephaly with or without ophthalmologic anomalies, and sensorineural hearing loss."

GeneReviews states moderate-to-severe intellectual disability as the typical MICPCH presentation in females.

PMID:33640666 SUPPORT Human Clinical

"we collected 34 patients (29 females) showing from moderate (4 patients) to severe (22) and profound (8) developmental delay"

Quantifies the severity distribution - all 34 individuals had at least moderate impairment. The band is held at VERY_FREQUENT rather than OBLIGATE because the 100% figure comes from a clinically ascertained cohort of 34 rather than an unselected population.

Global Developmental Delay VERY_FREQUENT HP:0001263

Show evidence (2 references)

PMID:24278995 SUPPORT Human Clinical

"Most are able to sit independently; 20%-25% attain the ability to walk; language is nearly absent in most."

GeneReviews quantifies the motor and language outcome, establishing severe global developmental delay.

PMID:22452838 SUPPORT Human Clinical

"Phenotype was variable in severity but highly similar among the 11 girls and was characterized by psychomotor retardation, severe intellectual disability, progressive microcephaly, dystonia, mild dysmorphism, and scoliosis."

Psychomotor retardation was a defining feature in all 11 girls of this series.

Absent or Severely Limited Speech FREQUENT Absent speech HP:0001344

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"language is nearly absent in most"

GeneReviews states language is nearly absent in most affected individuals; per the project frequency-mapping guidance the word most maps to the FREQUENT band in the absence of a numerator.

Pontocerebellar Hypoplasia VERY_FREQUENT HP:0001321

Show evidence (2 references)

PMID:33640666 SUPPORT Human Clinical

"all showed pontine and cerebellar hypoplasia"

All 34 individuals in this multicentre cohort had pontine and cerebellar hypoplasia. The band is held at VERY_FREQUENT rather than OBLIGATE because the cohort was ascertained partly on imaging, which inflates the apparent rate.

PMID:23901204 SUPPORT Human Clinical

"is characterized by neurodevelopmental delay, microcephaly, and disproportionate pontine and cerebellar hypoplasia"

States the defining clinico-radiological triad of the syndrome.

Ataxia OCCASIONAL HP:0001251

Show evidence (2 references)

PMID:40422253 SUPPORT Model Organism

"The CASK+/- HprteGFP/+ mice exhibited cerebellar ataxic phenotypes as judged by the scores of these experiments compared to the CASK wild-type control (CASK+/+ HprteGFP/+) mice."

The female heterozygous CASK-knockout mouse shows cerebellar ataxic phenotypes. This is model-organism evidence; human ataxia frequency in MICPCH is not separately quantified in the sources used here, which is why the band is set conservatively.

PMID:38670634 SUPPORT Model Organism

"We demonstrate that deletion of murine Cask after adulthood does not affect survival but leads to cerebellar degeneration and ataxia over time."

Post-adult conditional Cask deletion causes cerebellar degeneration and ataxia, showing an ongoing (not purely developmental) requirement for CASK in the cerebellum.

Dystonia FREQUENT HP:0001332

Show evidence (2 references)

PMID:22452838 SUPPORT Human Clinical

"characterized by psychomotor retardation, severe intellectual disability, progressive microcephaly, dystonia, mild dysmorphism, and scoliosis"

Dystonia was among the features characterising all 11 girls in this series.

PMID:24278995 SUPPORT Human Clinical

"dystonia or other movement disorders"

GeneReviews lists dystonia among the neurological features of MICPCH.

Seizures FREQUENT HP:0001250

Show evidence (3 references)

PMID:24278995 SUPPORT Human Clinical

"Nearly 40% have seizures by age ten years."

GeneReviews quantifies seizure frequency at nearly 40% by age ten, within the FREQUENT (30-79%) band.

PMID:33640666 SUPPORT Human Clinical

"Seventeen out of 34 patients (50%) suffered from epileptic seizures, including spasms (11 patients, 32.3%), generalized (5) or focal seizures (1)."

An independent cohort quantifies epilepsy at 50% with spasms as the commonest type, consistent with a FREQUENT band.

PMID:33640666 SUPPORT Human Clinical

"Drug resistance was frequent in our cohort (52.9% of patients with epilepsy)."

Quantifies drug resistance among those with epilepsy, informing management.

Epileptic Spasms FREQUENT HP:0011097

Show evidence (2 references)

PMID:33640666 SUPPORT Human Clinical

"including spasms (11 patients, 32.3%), generalized (5) or focal seizures (1)"

Spasms occurred in 32.3% of the whole cohort, within the FREQUENT (30-79%) band.

PMID:33640666 SUPPORT Human Clinical

"Seven (3 males) out of the 11 children with spasms showed EEG features and a course supporting the diagnosis of a developmental and epileptic encephalopathy (DEE)."

Documents progression to developmental and epileptic encephalopathy in the majority of those with spasms.

Sleep Disturbance FREQUENT HP:0002360

Show evidence (2 references)

PMID:41039189 SUPPORT Human Clinical

"Areas of frequent difficulty not highlighted in previous reports include sleep difficulties and cerebral visual impairment (CVI)."

Identifies sleep difficulties as an area of frequent difficulty in a systematically assessed cohort. Caveat - this cohort spans the whole CASK-related spectrum, in which MICPCH was less prevalent than in the historical literature, so the figure is not MICPCH-specific.

PMID:24278995 SUPPORT Human Clinical

"Behaviors may include sleep disturbances, hand stereotypies, and self biting."

GeneReviews lists sleep disturbance among the behavioural features.

Self-Injurious Behavior OCCASIONAL HP:0100716

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"Behaviors may include sleep disturbances, hand stereotypies, and self biting."

GeneReviews lists self-biting among the behavioural features; the hedged wording without a numerator supports a conservative OCCASIONAL band.

Growth 1

Growth Retardation FREQUENT Growth delay HP:0001510

Show evidence (1 reference)

PMID:21954287 SUPPORT Human Clinical

"severe postnatal microcephaly, often associated with growth retardation"

Growth retardation is described as often associated with the microcephaly in the defining phenotypic series.

Other 8

Inability to Walk FREQUENT HP:0002540

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"Most are able to sit independently; 20%-25% attain the ability to walk"

Only 20-25% attain walking, so 75-80% are unable to walk, which falls in the FREQUENT (30-79%) band.

Progressive Microcephaly VERY_FREQUENT HP:0000253

Course: PROGRESSIVE

Show evidence (2 references)

PMID:33640666 SUPPORT Human Clinical

"all showed pontine and cerebellar hypoplasia, all except three with microcephaly"

31 of 34 individuals (91%) had microcephaly, supporting a VERY_FREQUENT band.

PMID:21954287 SUPPORT Human Clinical

"Analysis of 20 patients in this study, and five previously reported patients, revealed a core clinical phenotype comprising severe developmental delay/intellectual disability, severe postnatal microcephaly, often associated with growth retardation"

Across a 25-patient series the core phenotype includes severe postnatal microcephaly, establishing the acquired, progressive character rather than a primary congenital small head.

Hypoplasia of the Pons VERY_FREQUENT HP:0012110

Show evidence (1 reference)

PMID:20595373 SUPPORT Human Clinical

"a reduced area of the cerebrum, pons, midbrain, and cerebellar vermis and hemispheres"

Quantitative morphometry documents reduced pontine area in individuals with CASK variants.

Axial Hypotonia FREQUENT HP:0008936

Show evidence (2 references)

PMID:24278995 SUPPORT Human Clinical

"Neurologic features may include axial hypotonia, hypertonia/spasticity of the extremities, and dystonia or other movement disorders."

GeneReviews lists axial hypotonia among the neurological features; the hedged wording maps to the FREQUENT band.

PMID:21954287 SUPPORT Human Clinical

"(axial) hypotonia with or without hypertonia of extremities"

Confirms axial hypotonia as part of the core clinical phenotype defined across 25 patients.

Optic Nerve Hypoplasia OCCASIONAL HP:0000609

Show evidence (2 references)

PMID:21954287 SUPPORT Human Clinical

"optic nerve hypoplasia, and/or other eye abnormalities"

Optic nerve hypoplasia is listed within the core clinical phenotype defined across 25 patients.

PMID:35670295 SUPPORT Human Clinical

"Additional findings, present in about one-third of individuals, include feeding difficulties, ophthalmologic issues, hypertonicity, epilepsy, and sensorineural hearing loss."

Bounds optic nerve hypoplasia from above - the broader "ophthalmologic issues" category as a whole affects about one-third, and optic nerve hypoplasia is only one member of that category, so the ONH-specific frequency must be below one-third, i.e. OCCASIONAL.

Cerebral Visual Impairment FREQUENT HP:0100704

Show evidence (1 reference)

PMID:41039189 SUPPORT Human Clinical

"Areas of frequent difficulty not highlighted in previous reports include sleep difficulties and cerebral visual impairment (CVI)."

Identifies cerebral visual impairment as an area of frequent difficulty, newly recognised relative to older reports. Caveat - this cohort spans the whole CASK-related spectrum, in which MICPCH was less prevalent than in the historical literature, so the figure is not MICPCH-specific.

Hand Stereotypies OCCASIONAL Motor stereotypy HP:0000733

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"Behaviors may include sleep disturbances, hand stereotypies, and self biting."

GeneReviews lists hand stereotypies among the behavioural features; the hedged "may include" wording without a numerator supports a conservative OCCASIONAL band.

Wide Nasal Bridge FREQUENT HP:0000431

Show evidence (1 reference)

PMID:21954287 SUPPORT Human Clinical

"A recognisable facial phenotype emerged, including prominent and broad nasal bridge and tip, small or short nose, long philtrum, small chin, and/or large ears."

Defines the recognisable facial gestalt, of which the broad nasal bridge is the leading component.

🧬

Genetic Associations

1

CASK (Causal - X-linked loss-of-function variants)

Gene: CASK hgnc:1497 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (4 references)

PMID:24278995 SUPPORT Human Clinical

"Microcephaly with pontine and cerebellar hypoplasia (MICPCH), generally associated with pathogenic loss-of-function variants in CASK. X-linked intellectual disability (XLID) with or without nystagmus, generally associated with hypomorphic CASK pathogenic variants."

GeneReviews states the genotype-phenotype split that defines the scope of this entry - null alleles give MICPCH, hypomorphic alleles give XLID.

PMID:28783747 SUPPORT Human Clinical

"CASK aberrations including a rare mosaic mutation in a male patient, were found in 32 cases, and a mutation in ITPR1, another known gene"

Quantifies the CASK contribution to a clinically ascertained MICPCH series and documents locus heterogeneity.

PMID:37628707 SUPPORT Human Clinical

"missense mutations associated with epilepsy and intellectual disability were found throughout the whole region of the CASK protein, while missense mutations related to microcephaly and MICPCH were restricted in certain domains"

Establishes a domain-level genotype-phenotype correlation - MICPCH-causing missense variants cluster in particular domains, whereas epilepsy/ID missense variants are distributed throughout the protein.

+ 1 more reference

💊

Medical Actions

7

Multidisciplinary Supportive Care

Action: supportive care Ontology label: Supportive Care NCIT:C15747

There is no disease-modifying therapy. Treatment is symptomatic and includes standard management of developmental delay and intellectual disability, antiseizure medication, nutritional support, physiotherapy, and treatment of abnormal vision and hearing loss.

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"Treatment is symptomatic and includes standard management of developmental delay and intellectual disability issues; medication for seizures; nutritional support; use of physiotherapy; and treatment of abnormal vision or hearing loss."

GeneReviews defines the standard of care as symptomatic multidisciplinary management.

Antiseizure Medication

Action: Pharmacotherapy NCIT:C15986

Seizures, most often epileptic spasms, require antiseizure treatment. Drug resistance is frequent, affecting over half of those with epilepsy, and epilepsy may appear or worsen over follow-up, so serial and systematic EEG and clinical monitoring is mandatory rather than optional.

Target Phenotypes: Seizure HP:0001250

Show evidence (2 references)

PMID:33640666 SUPPORT Human Clinical

"Drug resistance was frequent in our cohort (52.9% of patients with epilepsy)."

Quantifies the limited efficacy of antiseizure medication in this disorder, tempering the expected treatment benefit.

PMID:33640666 SUPPORT Human Clinical

"A childhood onset of epilepsy is frequent, with possible worsening over time, so that serial and systematic monitoring is mandatory."

Establishes the surveillance requirement that accompanies antiseizure management.

Physical Therapy and Motor Rehabilitation

Action: physical therapy Ontology label: Physical Therapy NCIT:C15302

Physiotherapy addresses the axial hypotonia, limb hypertonia, movement disorder and very limited ambulation, and supports scoliosis management.

Target Phenotypes: Axial hypotonia HP:0008936 Inability to walk HP:0002540

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"Treatment is symptomatic and includes standard management of developmental delay and intellectual disability issues; medication for seizures; nutritional support; use of physiotherapy; and treatment of abnormal vision or hearing loss."

GeneReviews' statement of symptomatic management names use of physiotherapy as one component of the standard treatment package.

Nutritional Support

Action: nutritional support Ontology label: Nutritional Support NCIT:C15433

Feeding difficulties affect roughly a third of individuals and are managed with nutritional support, up to and including enteral feeding.

Target Phenotypes: Feeding difficulties HP:0011968

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"Treatment is symptomatic and includes standard management of developmental delay and intellectual disability issues; medication for seizures; nutritional support; use of physiotherapy; and treatment of abnormal vision or hearing loss."

GeneReviews' statement of symptomatic management names nutritional support as one component of the standard treatment package.

Vision and Hearing Management

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Treatment of abnormal vision and of sensorineural hearing loss is part of standard care, and cerebral visual impairment specifically warrants assessment given its recently recognised frequency.

Target Phenotypes: Sensorineural hearing impairment HP:0000407 Cerebral visual impairment HP:0100704

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"treatment of abnormal vision or hearing loss"

GeneReviews includes treatment of vision and hearing abnormalities in standard management.

JNK Inhibition (Preclinical)

Action: Pharmacotherapy NCIT:C15986

JNK-IN-8, a Jun N-terminal kinase inhibitor, suppresses CASK-deficiency-induced cerebellar granule cell death in vitro by reducing reactive oxygen species, and intracerebellar injection suppresses granule cell death and alleviates ataxic phenotypes in heterozygous CASK-knockout mice. This is the only mechanism-directed therapeutic lead in the disorder. It is entirely preclinical - there are no human data, and intracerebellar delivery is not clinically translatable as tested.

Mechanism Target:

INHIBITS Cerebellar Granule Cell Apoptosis via JNK/ROS Signalling — JNK inhibition blocks the apoptotic pathway driving cerebellar granule cell death, the node immediately upstream of the cerebellar hypoplasia.

Show evidence (1 reference)

PMID:40422253 SUPPORT Model Organism

"JNK-IN-8 suppresses the cell death and activation of the ROS pathway in CASK-KO CG cells in both in vitro and in vivo models, suggesting its potential as a therapeutic strategy for cerebellar neurodegeneration in MICPCH syndrome."

Establishes JNK inhibition as a preclinical therapeutic strategy; the evidence is entirely from mouse and cell models.

Genetic Counseling

Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Counselling covers X-linked inheritance, the predominance of de novo variants, the point that an asymptomatic mother is unlikely to be a heterozygote because heterozygous females manifest the disorder, the possibility of parental germline mosaicism, and prenatal/preimplantation testing once a familial variant is known.

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"Risk to the family members of a proband with a CASK disorder depends on the phenotype (i.e., MICPCH or XLID ± nystagmus) in the proband."

GeneReviews states that recurrence-risk counselling is phenotype-dependent within the CASK spectrum.

🔬

Diagnosis

3

Molecular Genetic Testing for CASK (Positive in affected individuals)

The diagnosis is established by identifying a heterozygous (female) or hemizygous (male) pathogenic CASK variant. Because a large fraction of pathogenic alleles are copy-number changes, testing must combine sequencing with deletion/duplication analysis (chromosomal microarray, MLPA or array-CGH); sequencing alone will miss them. Rarely, affected males carry the variant in a mosaic state, which requires appropriately sensitive testing.

molecular genetic testing NCIT:C19770

Show evidence (2 references)

PMID:24278995 SUPPORT Human Clinical

"The diagnosis of a CASK disorder is established in a female who is heterozygous for a CASK pathogenic variant and in a male who is hemizygous for a CASK pathogenic variant on molecular genetic testing. Rarely, affected males have a mosaic pathogenic variant."

GeneReviews states the molecular diagnostic criterion and flags male mosaicism.

PMID:23901204 SUPPORT Human Clinical

"an array-comparative genomic hybridization (a-CGH) analysis showed CASK gene duplication at Xp11.4"

Illustrates that copy-number analysis is required, since conventional cytogenetics was normal in this case.

Brain MRI with Posterior Fossa Morphometry (Abnormal in essentially all affected individuals)

MRI showing disproportionate pontine and cerebellar hypoplasia with a dilated fourth ventricle, combined with a normal-sized corpus callosum and a low cerebrum/corpus callosum area ratio, is highly suggestive and distinguishes CASK-related pontocerebellar hypoplasia from other pontocerebellar hypoplasias, in which the corpus callosum is thinned.

magnetic resonance imaging NCIT:C16809

Show evidence (3 references)

PMID:20595373 SUPPORT Human Clinical

"The 5 patients with pontine hypoplasia showed thinning of the corpus callosum and a high ratio of the cerebrum/corpus callosum, irrespective of the size of the cerebrum."

Establishes the contrast with non-CASK pontine hypoplasia, in which the corpus callosum is thinned and the ratio is high.

PMID:20595373 SUPPORT Human Clinical

"The normal size of the corpus callosum, which gives an impression of callosal thickening at first glance, may be an imaging clue to detect patients with CASK mutations."

Identifies the specific imaging clue that should prompt CASK testing.

PMID:21954287 SUPPORT Human Clinical

"The combination of developmental and brain imaging features together with mild facial dysmorphism is highly suggestive of this disorder and should prompt subsequent testing of the CASK gene."

States that the combined clinical-radiological gestalt should prompt CASK testing.

Electroencephalography (Abnormal in individuals with epilepsy, which affects roughly 40-50% of individuals)

EEG is indicated whenever seizures, epileptic spasms, developmental regression or suspicious paroxysmal events occur, and it characterizes the epilepsy rather than merely confirming it: in a genetically confirmed CASK cohort the EEG showed poorly organized background activity with diffuse or multifocal epileptiform abnormalities and sleep activation, and in the majority of children with spasms the EEG features and course supported a diagnosis of developmental and epileptic encephalopathy. Because epilepsy onset is frequently in childhood and the abnormalities may appear only over the follow-up period, a single normal study does not exclude later epilepsy and serial systematic monitoring is required.

electroencephalography NCIT:C38054

Show evidence (2 references)

PMID:33640666 SUPPORT Human Clinical

"EEG abnormalities included poorly organized background activity with diffuse or multifocal epileptiform abnormalities and sleep-activation, with possible appearance over the follow-up period."

Describes the characteristic EEG findings in a CASK cohort and notes that they may emerge only on follow-up, which is why the study is repeated rather than performed once.

PMID:33640666 SUPPORT Human Clinical

"Seven (3 males) out of the 11 children with spasms showed EEG features and a course supporting the diagnosis of a developmental and epileptic encephalopathy (DEE)."

Shows that the EEG is what distinguishes developmental and epileptic encephalopathy from spasms alone in this disorder.

📊

Prevalence

1

🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from MICPCH Syndrome:

Pontocerebellar Hypoplasia Type 2 (TSEN54)

Overlapping Features The commonest form of pontocerebellar hypoplasia and the main radiological differential; it is autosomal recessive and shows a thinned corpus callosum, whereas the corpus callosum is of normal size in CASK-related MICPCH. In one reference centre CASK-related PCH was the second most frequent cause of PCH.

Rett Syndrome (MECP2)

Overlapping Features Shares severe intellectual disability in females, acquired microcephaly, hand stereotypies and absent speech; distinguished by the CASK imaging signature and by molecular testing.

Congenital Disorders of Glycosylation

Overlapping Features A recognised cause of cerebellar hypoplasia with developmental delay that should be excluded biochemically.

🐁

Animal Models

1

CASK heterozygous knockout (CASK+/-) female, with X-linked GFP reporter Mouse

Female heterozygous CASK-knockout mice replicate the progressive cerebellar hypoplasia and motor deficits of MICPCH. Combined with an X-linked GFP reporter they allow direct visualisation of the CASK-positive/CASK-negative mosaic and of the selective postnatal elimination of the CASK-negative population.

Species

Mouse

Genotype

CASK heterozygous knockout (CASK+/-) female, with X-linked GFP reporter

Genes

CASK hgnc:1497

Show evidence (2 references)

PMID:40422238 SUPPORT Model Organism

"The CASK-hKO mice exhibited motor deficits and cerebellar hypoplasia similar to those observed in patients with CASK-related disorders."

Establishes face validity of the female heterozygous knockout mouse for the human cerebellar and motor phenotype.

PMID:37190086 SUPPORT Model Organism

"Female CASK heterozygote KO mice replicate the progressive cerebellar hypoplasia observed in MICPCH syndrome."

Independently confirms that the female heterozygous knockout reproduces the progressive cerebellar hypoplasia.

{ }

Source YAML

click to show

name: MICPCH Syndrome
creation_date: "2026-07-31T00:00:00Z"
description: >-
  MICPCH (microcephaly with pontine and cerebellar hypoplasia; syndromic X-linked
  intellectual disability, Najm type; OMIM 300749) is an X-linked
  neurodevelopmental disorder caused by loss-of-function variants in CASK
  (Xp11.4), which encodes calcium/calmodulin-dependent serine protein kinase, a
  MAGUK-family presynaptic scaffold protein. It is the severe end of the
  CASK-related disorder spectrum and is seen predominantly in heterozygous
  females, in whom random X-chromosome inactivation produces a mosaic of
  CASK-expressing and CASK-deficient neurons. The core phenotype is
  moderate-to-severe intellectual disability with severe motor delay, progressive
  postnatal microcephaly, and a characteristic neuroimaging picture of
  disproportionate pontine and cerebellar hypoplasia with a relatively preserved
  corpus callosum. Additional features include axial hypotonia with limb
  hypertonia/spasticity, dystonia and other movement disorders, epilepsy in
  roughly 40-50%, optic nerve hypoplasia and other ophthalmological anomalies,
  sensorineural hearing loss, feeding difficulties, growth retardation, scoliosis,
  sleep disturbance, hand stereotypies and self-biting, and a mild recognisable
  facial gestalt. Affected males are far rarer and usually have a
  severe-to-profound phenotype with early intractable epilepsy, unless the variant
  is mosaic or hypomorphic.
category: Mendelian
parents:
- Neurodevelopmental Disorder
- Syndromic Intellectual Disability
- Pontocerebellar Hypoplasia
notes: >-
  Scope and disambiguation. CASK causes a clinical continuum, and this entry is
  scoped to the MICPCH end of it (MONDO:0010417 / OMIM 300749), i.e. the
  loss-of-function phenotype with pontocerebellar hypoplasia. Two other CASK
  phenotypes are deliberately NOT curated here: (i) X-linked intellectual
  disability with or without nystagmus (FGS4/MRXSNA, OMIM 300422), which is
  caused by hypomorphic missense and splice variants and typically affects males
  with unaffected or mildly affected carrier females, and (ii) X-linked optic
  atrophy (OMIM 300711). Where the MICPCH literature necessarily discusses the
  full CASK spectrum, the distinction is made explicit in the relevant
  description or explanation so that the two arms are not conflated. The
  parent MONDO class MONDO:1060192 "CASK-related intellectual disability"
  explicitly spans both arms and is intentionally not used as the `disease_term`.
  MONDO:0010417 is used because its OMIM xref is 300749 (the MICPCH entry), even
  though its Orphanet-derived textual definition is itself broad enough to
  mention nystagmus; the OMIM anchor, not the prose, fixes the identity.
  Module conformance. `cerebellar_purkinje_degeneration` was evaluated and
  rejected: its trigger node is Purkinje-cell calcium/proteostasis dysregulation
  driving Purkinje neuron degeneration and cerebellar ataxia, and MICPCH does not
  instantiate that trigger. The MICPCH lesion is developmental loss of a
  MAGUK scaffold, with the demonstrated proximate mechanism being JNK/ROS-driven
  apoptosis of cerebellar GRANULE cells (the cell type used in every rescue and
  drug experiment in this disorder). CASK-negative Purkinje cells are also
  eliminated in the mosaic female mouse, so this is not a claim that Purkinje
  cells are spared - it is that the module's calcium/proteostasis trigger and
  Purkinje-primary framing are not what the CASK evidence shows. `epilepsy_excitation_inhibition_imbalance` was also evaluated; the
  epilepsy here is a frequent comorbidity of the developmental lesion rather than
  a curated excitation/inhibition-imbalance chain, so no conformance is declared.
disease_term:
  preferred_term: MICPCH syndrome
  term:
    id: MONDO:0010417
    label: syndromic X-linked intellectual disability Najm type
synonyms:
- MICPCH
- microcephaly with pontine and cerebellar hypoplasia
- X-linked intellectual disability-microcephaly-pontocerebellar hypoplasia syndrome
- mental retardation and microcephaly with pontine and cerebellar hypoplasia
- syndromic X-linked intellectual disability Najm type
- CASK-related MICPCH
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  - classification_value: NEUROLOGIC
references:
- reference: PMID:24278995
  title: "CASK Disorders."
  tags:
  - GeneReviews
prevalence:
- population: Published individuals worldwide (all CASK-related disorders)
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Over 175 individuals with pathogenic CASK variants across the whole
    CASK-related spectrum had been reported by 2022; a systematic review in 2025
    identified 151 published individuals. No population prevalence estimate has
    been established for MICPCH.
  evidence:
  - reference: PMID:35670295
    reference_title: "Pathogenic variants in CASK: Expanding the genotype-phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In total, over 175 patients have been reported in the literature."
    explanation: Quantifies the total published CASK-variant caseload, supporting an ultra-rare classification in the absence of a population prevalence estimate.
  - reference: PMID:41039189
    reference_title: "The neurodevelopmental spectrum of CASK-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One hundred and fifty-one individuals with CASK variants were identified in published literature."
    explanation: A 2025 systematic review independently counts the published CASK caseload.
inheritance:
- name: X-linked inheritance, typically de novo
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  expressivity: VARIABLE
  description: >-
    MICPCH is inherited in an X-linked manner. Almost all affected individuals
    are simplex cases resulting from a de novo CASK loss-of-function variant.
    Because heterozygous females manifest the phenotype, an asymptomatic mother
    is unlikely to be a heterozygote, which is the key counselling point.
    Hemizygous males with a true loss-of-function allele have a
    severe-to-profound phenotype with early, often intractable epilepsy; the
    small number of more mildly affected males carry the variant in the mosaic
    state or carry a hypomorphic allele.
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CASK disorders are inherited in an X-linked manner."
    explanation: GeneReviews states the mode of inheritance.
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most affected females and males represent simplex cases (i.e., the only affected family member) and have the disorder as the result of a de novo CASK pathogenic variant. Because heterozygous females manifest the phenotype, an asymptomatic mother is unlikely to be heterozygous for the CASK pathogenic variant."
    explanation: Establishes the predominance of de novo variants and the counselling implication that asymptomatic mothers are unlikely to be carriers.
  - reference: PMID:22452838
    reference_title: "Spectrum of pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As expected in an X-linked disease manifesting mainly in females, the boy hemizygous for a splice mutation had a very severe phenotype with nearly no development and refractory epilepsy. We described a mild phenotype in a boy with a mosaic truncating mutation."
    explanation: Demonstrates the sex-dependent severity gradient and the ameliorating effect of somatic mosaicism in males.
pathophysiology:
- name: CASK Loss of Function
  biological_scale: MOLECULAR
  description: >-
    Heterozygous (female) or hemizygous (male) null alleles of CASK at Xp11.4 -
    whole- and partial-gene deletions, intragenic duplications, nonsense,
    frameshift and splice variants - abolish CASK protein. In fibroblasts from
    individuals with a CASK loss-of-function variant no CASK protein is
    detectable, whereas mosaic or hypomorphic alleles leave residual protein,
    which is the molecular basis of the MICPCH-versus-XLID split. A minority of
    MICPCH-causing alleles are missense variants that destroy a specific
    protein-protein interface rather than the whole protein.
  genes:
  - preferred_term: CASK
    term:
      id: hgnc:1497
      label: CASK
  molecular_functions:
  - preferred_term: protein-macromolecule adaptor activity
    term:
      id: GO:0030674
      label: protein-macromolecule adaptor activity
    modifier: DECREASED
  downstream:
  - target: Disrupted CASK-Neurexin Presynaptic Scaffold Interaction
    causal_link_type: DIRECT
    description: >-
      Loss of CASK removes the PDZ-domain-mediated link to presynaptic neurexins.
  - target: Disrupted CASK-Liprin-alpha2 Interaction via the CaMK Domain
    causal_link_type: DIRECT
    description: >-
      Loss of CASK removes the CaMK-domain-mediated link to Liprin-alpha2 that
      cerebellar granule cell survival depends on.
  - target: X-Linked Mosaicism and Competitive Cerebellar Cell Loss
    causal_link_type: DIRECT
    description: >-
      In heterozygous females, random X-inactivation creates a mosaic of
      CASK-positive and CASK-negative neurons that then compete.
  - target: Splice-Dependent Regional Specialisation of CASK Function
    causal_link_type: DIRECT
    description: >-
      Which CASK functions are lost depends on which alternatively spliced exons
      the variant affects, which is why the cerebellar and forebrain phenotypes
      can be genetically separated.
  - target: Excitatory-Inhibitory Synaptic Imbalance via GluN2B Downregulation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Loss of CASK downregulates the NMDA receptor subunit GluN2B and shifts the
      excitatory/inhibitory balance. This edge is deliberately parented on the
      gene-level lesion rather than on the neurexin interface: the GluN2B effect
      has been attributed to CASK's nuclear/TBR1-cooperative role, which is a
      different interface from the presynaptic neurexin one, and the responsible
      interface is an open question recorded in `discussions`.
  evidence:
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "11 submicroscopic copy number alterations, including nine deletions of ~11 kb to 4.5 Mb and two duplications, all covering (part of) CASK, four splice, four nonsense, and one 1 bp deletion are reported. These heterozygous CASK mutations most likely lead to a null allele."
    explanation: Documents the loss-of-function variant spectrum and establishes that these alleles are functionally null.
  - reference: PMID:25886057
    reference_title: "Phenotypic and molecular insights into CASK-related disorders in males."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In fibroblasts from patients with a CASK loss-of-function mutation, no CASK protein could be detected. Individuals who are mosaic for a severe CASK mutation or carry a hypomorphic mutation still showed detectable amount of protein."
    explanation: Direct protein-level demonstration that MICPCH alleles are null while mosaic/hypomorphic alleles retain protein, explaining the phenotypic split.
- name: Disrupted CASK-Neurexin Presynaptic Scaffold Interaction
  biological_scale: MOLECULAR
  description: >-
    CASK binds the cytoplasmic tail of presynaptic neurexins through its PDZ
    domain, coupling the presynaptic adhesion machinery to the intracellular
    scaffold. Two MICPCH-causing missense variants in heterozygous girls
    (p.Met519Thr in the PDZ domain, p.Gly659Asp in the SH3 domain) each abolish
    neurexin binding while other aggregation-inducing CASK variants that leave
    the interaction intact do not cause MICPCH. This dissociates the neurexin
    interface from the previously assumed CASK-TBR1 transcriptional interface as
    the critical one for microcephaly and cerebellar hypoplasia.
  biological_processes:
  - preferred_term: synapse organization
    term:
      id: GO:0050808
      label: synapse organization
    modifier: DECREASED
  downstream:
  - target: Impaired Cortical Excitatory Synaptic Maturation and Network Activity
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Loss of the presynaptic CASK-neurexin scaffold degrades synaptic
      transmission in cortical excitatory neurons.
  - target: Postnatal Brain Growth Failure and Progressive Microcephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Variants that specifically disrupt the CASK-neurexin interface are
      sufficient to produce microcephaly and hindbrain hypoplasia in humans.
  evidence:
  - reference: PMID:29426960
    reference_title: "Two microcephaly-associated novel missense mutations in CASK specifically disrupt the CASK-neurexin interaction."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The mutation M519T results in the replacement of an evolutionarily invariant methionine located in the PDZ signaling domain known to be critical for the CASK-neurexin interaction. CASKM519T is incapable of binding to neurexin, suggesting a critically important role for the CASK-neurexin interaction."
    explanation: Direct biochemical demonstration that a MICPCH-causing missense variant abolishes neurexin binding.
  - reference: PMID:29426960
    reference_title: "Two microcephaly-associated novel missense mutations in CASK specifically disrupt the CASK-neurexin interaction."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our results suggest that disruption of the CASK-neurexin interaction, not the CASK-Tbr-1 interaction, produces microcephaly and cerebellar hypoplasia."
    explanation: Identifies the neurexin interface rather than the TBR1 interface as the critical one for the MICPCH brain phenotype.
- name: Disrupted CASK-Liprin-alpha2 Interaction via the CaMK Domain
  biological_scale: MOLECULAR
  description: >-
    Rescue mapping in CASK-knockout cerebellar granule cells shows that the CaMK,
    PDZ and SH3 domains - but not the L27 or guanylate kinase domains - are
    required for granule cell survival. Patient-derived missense variants in the
    CaMK domain fail to rescue granule cell death, and structural prediction
    places them at the Liprin-alpha2 binding interface, implicating loss of the
    CASK-Liprin-alpha2 interaction as the proximate cause of granule cell death.
  molecular_functions:
  - preferred_term: protein-macromolecule adaptor activity
    term:
      id: GO:0030674
      label: protein-macromolecule adaptor activity
    modifier: DECREASED
  downstream:
  - target: Cerebellar Granule Cell Apoptosis via JNK/ROS Signalling
    causal_link_type: DIRECT
    description: >-
      Loss of the CaMK-domain-mediated Liprin-alpha2 interaction removes the
      survival signal for cerebellar granule cells.
  evidence:
  - reference: PMID:37190086
    reference_title: "Structural Analysis Implicates CASK-Liprin-α2 Interaction in Cerebellar Granular Cell Death in MICPCH Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Rescue experiments with CASK deletion mutants identify that the CaMK, PDZ, and SH3, but not L27 and guanylate kinase domains of CASK are required for the survival of CG cells."
    explanation: Domain-mapping rescue experiments localise the granule-cell survival function to specific CASK domains.
  - reference: PMID:37190086
    reference_title: "Structural Analysis Implicates CASK-Liprin-α2 Interaction in Cerebellar Granular Cell Death in MICPCH Syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Machine learning-based structural analysis using AlphaFold 2.2 predicts that these mutations disrupt the structure of the binding interface with Liprin-α2."
    explanation: The Liprin-alpha2 interface assignment rests on AlphaFold structural prediction rather than direct structure determination, so this is curated as partial computational support.
- name: Cerebellar Granule Cell Apoptosis via JNK/ROS Signalling
  biological_scale: CELLULAR
  description: >-
    CASK-knockout cerebellar granule cells undergo progressive apoptosis with
    activation of intracellular Jun N-terminal kinase signalling and upregulation
    of reactive-oxygen-species-related gene expression. Pharmacological JNK
    inhibition with JNK-IN-8 increases granule cell survival in vitro by reducing
    ROS generation, and intracerebellar injection suppresses granule cell death
    and alleviates ataxic behaviour in heterozygous CASK-knockout mice, making
    this the first tractable therapeutic node in the disorder. This granule-cell
    death mechanism is the reason the entry does not conform to the
    Purkinje-centred cerebellar degeneration module.
  cell_types:
  - preferred_term: cerebellar granule cell
    term:
      id: CL:0001031
      label: cerebellar granule cell
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  - preferred_term: cerebellar granular layer morphogenesis
    term:
      id: GO:0021683
      label: cerebellar granular layer morphogenesis
    modifier: ABNORMAL
  downstream:
  - target: Progressive Pontine and Cerebellar Hypoplasia
    causal_link_type: DIRECT
    description: >-
      Cumulative granule cell loss produces the progressive cerebellar hypoplasia
      seen on serial imaging.
  evidence:
  - reference: PMID:40422253
    reference_title: "Jun N-Terminal Kinase Inhibitor Suppresses CASK Deficiency-Induced Cerebellar Granular Cell Death in MICPCH Syndrome Model Mice."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We performed RNA-sequencing (RNA-seq) on these cells and found that CASK-KO CG cells underwent apoptosis by activating intracellular Jun N-terminal kinase (JNK) signaling and upregulating reactive oxygen species (ROS)-related gene expression."
    explanation: Identifies JNK activation and ROS upregulation as the apoptotic pathway in CASK-deficient cerebellar granule cells.
  - reference: PMID:40422253
    reference_title: "Jun N-Terminal Kinase Inhibitor Suppresses CASK Deficiency-Induced Cerebellar Granular Cell Death in MICPCH Syndrome Model Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "injection of JNK-IN-8 into the cerebellum of CASK+/- HprteGFP/+ mice suppressed CG cell death and alleviated cerebellar ataxic phenotypes in vivo"
    explanation: In vivo rescue of granule cell death and ataxia by JNK inhibition, establishing this node as causally upstream of the cerebellar phenotype and as a therapeutic target.
  - reference: PMID:37190086
    reference_title: "Structural Analysis Implicates CASK-Liprin-α2 Interaction in Cerebellar Granular Cell Death in MICPCH Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "CASK KO cultured cerebellar granule (CG) cells show progressive cell death that can be rescued by co-infection with lentivirus expressing wild-type CASK."
    explanation: Establishes that granule cell death is cell-autonomously caused by CASK loss and is reversible by CASK restoration.
- name: X-Linked Mosaicism and Competitive Cerebellar Cell Loss
  biological_scale: CELLULAR
  description: >-
    Because CASK is subject to X-chromosome inactivation, heterozygous females
    carry a mosaic of CASK-expressing and CASK-deficient neurons. In the female
    heterozygous knockout mouse, roughly half of cerebellar granule cells are
    CASK-negative during early postnatal development, yet almost all surviving
    granule and Purkinje cells are CASK-positive in adulthood - the CASK-negative
    population is selectively eliminated. Comparison with hypomorphic mice
    indicates the survival of granule cells is set by a combination of
    cell-autonomous and cell-competitive mechanisms. This explains why the female
    phenotype is severe rather than mitigated by mosaicism, and why total cell
    number, not just cell function, is reduced.
  cell_types:
  - preferred_term: cerebellar granule cell
    term:
      id: CL:0001031
      label: cerebellar granule cell
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  downstream:
  - target: Progressive Pontine and Cerebellar Hypoplasia
    causal_link_type: DIRECT
    description: >-
      Selective elimination of the CASK-deficient neuronal population reduces
      cerebellar cell number and cortical thickness.
  evidence:
  - reference: PMID:40422238
    reference_title: "The Competitive Loss of Cerebellar Granule and Purkinje Cells Driven by X-Linked Mosaicism in a Female Mouse Model of CASK-Related Disorders."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "although half of the cerebellar granule cells were CASK-negative during early postnatal development, almost all Purkinje cells and cerebellar granule cells were CASK-positive in adulthood, suggesting that CASK expression may determine the survival of cerebellar granule cells during postnatal development"
    explanation: Demonstrates selective postnatal elimination of the CASK-negative neuronal population in the mosaic female brain.
  - reference: PMID:40422238
    reference_title: "The Competitive Loss of Cerebellar Granule and Purkinje Cells Driven by X-Linked Mosaicism in a Female Mouse Model of CASK-Related Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The CASK gene is regulated by X-chromosome inactivation, which results in a mosaic distribution of CASK-expressing and CASK-deficient neurons in the female brain."
    explanation: Background statement of the X-inactivation mosaicism premise (about the human female brain, not the mouse result); tagged OTHER because it is framing rather than data. The experimental finding is carried by the preceding item.
- name: Impaired Cortical Excitatory Synaptic Maturation and Network Activity
  biological_scale: CELLULAR
  description: >-
    In isogenic human embryonic stem cell-derived cortical excitatory induced
    neurons, CASK knockout leaves immature neuronal outgrowth, synapse number and
    neuronal morphology intact but produces severe defects in synaptic
    transmission and in synchronised network activity as the neurons mature.
    CASK therefore acts on the functional maturation of cortical excitatory
    networks rather than on their gross structural assembly, which is consistent
    with the clinical picture of profound cognitive and language impairment out
    of proportion to any cortical malformation.
  cell_types:
  - preferred_term: cerebral cortex neuron
    term:
      id: CL:0010012
      label: cerebral cortex neuron
  biological_processes:
  - preferred_term: synapse assembly
    term:
      id: GO:0007416
      label: synapse assembly
    modifier: ABNORMAL
  downstream:
  - target: Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Degraded excitatory network function underlies the cognitive impairment.
  - target: Absent or Severely Limited Speech
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The same cortical network deficit underlies the near-absent expressive
      language.
  evidence:
  - reference: PMID:36262316
    reference_title: "CASK loss of function differentially regulates neuronal maturation and synaptic function in human induced cortical excitatory neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "While immature CASK KO iNs show robust neuronal outgrowth, mature CASK KO iNs display severe defects in synaptic transmission and synchronized network activity without compromising neuronal morphology and synapse numbers."
    explanation: Isogenic human neuron model shows the deficit is in synaptic function and network synchrony rather than in neuronal morphology or synapse number.
  - reference: PMID:36262316
    reference_title: "CASK loss of function differentially regulates neuronal maturation and synaptic function in human induced cortical excitatory neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In the developing human cortical excitatory neurons, CASK functions to promote both structural integrity and establishment of cortical excitatory neuronal networks."
    explanation: Summarises CASK's role in establishing human cortical excitatory networks. The wording about structural integrity refers to CASK's role across development generally; in this specific isogenic assay the mature-neuron deficit was functional (transmission and network synchrony) with morphology and synapse number preserved, as stated in the node description.
- name: Excitatory-Inhibitory Synaptic Imbalance via GluN2B Downregulation
  biological_scale: CELLULAR
  description: >-
    Exploiting X-chromosome inactivation in heterozygous female CASK-knockout
    mice, CASK-deficient and CASK-expressing neurons can be compared side by side
    in the same slice. Both CASK-knockout and CASK-knockdown neurons show a
    disrupted excitatory/inhibitory balance, the NMDA receptor subunit GluN2B is
    downregulated, and overexpressing GluN2B rescues the imbalance - identifying
    GluN2B loss as a mediator. This is a distinct, postsynaptic-facing arm of the
    mechanism from the presynaptic CASK-neurexin scaffold arm, and it provides a
    plausible substrate for the epilepsy seen in roughly half of individuals.
  cell_types:
  - preferred_term: cerebral cortex neuron
    term:
      id: CL:0010012
      label: cerebral cortex neuron
  biological_processes:
  - preferred_term: synapse organization
    term:
      id: GO:0050808
      label: synapse organization
    modifier: ABNORMAL
  downstream:
  - target: Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      A shifted excitatory/inhibitory balance is a plausible substrate for the
      epilepsy, though this link has been demonstrated in mouse rather than human
      tissue.
  evidence:
  - reference: PMID:30610199
    reference_title: "Deficiency of calcium/calmodulin-dependent serine protein kinase disrupts the excitatory-inhibitory balance of synapses by down-regulating GluN2B."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Both CASK-KO and CASK-KD neurons showed a disruption of the excitatory and inhibitory (E/I) balance."
    explanation: Establishes disrupted excitatory/inhibitory balance as a direct consequence of CASK loss in mouse cortical neurons.
  - reference: PMID:30610199
    reference_title: "Deficiency of calcium/calmodulin-dependent serine protein kinase disrupts the excitatory-inhibitory balance of synapses by down-regulating GluN2B."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We further found that the expression level of the N-methyl-D-aspartate receptor subunit GluN2B was decreased in CASK-KD neurons and that overexpressing GluN2B rescued the disrupted E/I balance in CASK-KD neurons."
    explanation: Identifies GluN2B downregulation as the mediator, with rescue by GluN2B overexpression establishing causality within the model.
- name: Splice-Dependent Regional Specialisation of CASK Function
  biological_scale: MOLECULAR
  description: >-
    Two vertebrate-specific CASK exons in the central part of the protein are
    alternatively spliced differently in forebrain and hindbrain, and their
    inclusion alters the structure of the CASK C-terminus. Damaging hemizygous
    variants clustered in exactly these exons produce boys with microcephaly and
    cerebral dysfunction but WITHOUT pontocerebellar hypoplasia. This is a third
    genotype class alongside the null (MICPCH) and hypomorphic (XLID) alleles,
    and it explains how the cerebellar and forebrain consequences of CASK loss
    can be genetically separated. It also implies an ongoing, non-developmental
    cerebellar requirement, since deleting Cask in adult mice causes cerebellar
    degeneration.
  genes:
  - preferred_term: CASK
    term:
      id: hgnc:1497
      label: CASK
  downstream:
  - target: Cerebellar Granule Cell Apoptosis via JNK/ROS Signalling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Loss of CASK function disproportionately affects the cerebellum, and the
      granule cell population is the demonstrated site of that vulnerability.
  evidence:
  - reference: PMID:38670634
    reference_title: "Genetic evidence for splicing-dependent structural and functional plasticity in CASK protein."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intriguingly, damaging hemizygous CASK mutations in boys who display microcephaly and cerebral dysfunction but without PCH are known. These mutations are present in two vertebrate-specific CASK exons."
    explanation: Human genetic evidence that variants in two specific vertebrate-specific exons uncouple microcephaly from pontocerebellar hypoplasia.
  - reference: PMID:38670634
    reference_title: "Genetic evidence for splicing-dependent structural and functional plasticity in CASK protein."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These exons are subject to alternative splicing both in forebrain and hindbrain. Inclusion of these exons differentially affects the molecular structure and hence possibly the function/s of the CASK C-terminus."
    explanation: RT-PCR and in silico structural analysis showing region-differential splicing of these exons and its structural consequence; tagged OTHER because it combines molecular-biology and computational structural evidence.
  - reference: PMID:38670634
    reference_title: "Genetic evidence for splicing-dependent structural and functional plasticity in CASK protein."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Loss of CASK function disproportionately affects the cerebellum."
    explanation: States the regional selectivity of CASK loss that this node captures.
- name: Progressive Pontine and Cerebellar Hypoplasia
  biological_scale: TISSUE
  description: >-
    The neuroimaging hallmark is diffuse brainstem and cerebellar hypoplasia with
    a dilated fourth ventricle, of markedly varying degree. Quantitative
    morphometry distinguishes it from other pontocerebellar hypoplasias: the pons,
    midbrain, cerebellar vermis and hemispheres and the cerebrum are all reduced,
    but the corpus callosum is of normal size, giving a low cerebrum/corpus
    callosum ratio - the opposite of the pattern in other causes of pontine
    hypoplasia. Vermis hypoplasia severity correlates with clinical severity.
    Whether the cerebellar hypoplasia is truly progressive in humans is unsettled:
    the female heterozygous mouse shows progressive cerebellar hypoplasia and
    post-adult conditional deletion causes cerebellar degeneration and ataxia over
    time, but the human microcephaly with PCH has also been characterised as
    self-limiting, so this entry does not assert human progression.
  locations:
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  - preferred_term: pons
    term:
      id: UBERON:0000988
      label: pons
  biological_processes:
  - preferred_term: cerebellum development
    term:
      id: GO:0021549
      label: cerebellum development
    modifier: ABNORMAL
  downstream:
  - target: Pontocerebellar Hypoplasia
    causal_link_type: DIRECT
    description: The tissue-level lesion is the imaging phenotype.
  - target: Postnatal Brain Growth Failure and Progressive Microcephaly
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Hindbrain volume loss contributes to the overall reduction in brain growth.
  evidence:
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain imaging consistently showed diffuse brainstem and cerebellar hypoplasia with a dilated fourth ventricle, but of remarkably varying degrees."
    explanation: Establishes the consistent but variable brainstem-cerebellar imaging phenotype across a 25-patient series.
  - reference: PMID:20595373
    reference_title: "Neuroradiologic features of CASK mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MR imaging in patients with CASK mutations revealed a normal size of the corpus callosum and a low ratio of the cerebrum/corpus callosum with a reduced area of the cerebrum, pons, midbrain, and cerebellar vermis and hemispheres."
    explanation: Quantitative morphometry defining the CASK-specific imaging signature and distinguishing it from other pontine hypoplasias.
  - reference: PMID:22452838
    reference_title: "Spectrum of pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found some degree of correlation between severity of the vermis hypoplasia and clinical phenotype."
    explanation: Links the degree of vermis hypoplasia to clinical severity.
- name: Postnatal Brain Growth Failure and Progressive Microcephaly
  biological_scale: ORGANISM
  description: >-
    Head growth decelerates rather than being congenitally arrested, producing
    progressive postnatal microcephaly. Prenatal imaging shows this process can
    begin in utero: progressive deceleration of fetal head circumference growth
    rate was seen in 15 of 19 fetuses with available data, with a subset already
    below -2 SD and some with a small transcerebellar diameter, although most
    cases would not be picked up by current routine fetal CNS assessment.
  downstream:
  - target: Progressive Microcephaly
    causal_link_type: DIRECT
    description: The organism-level growth failure is the clinical microcephaly.
  - target: Growth Retardation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Somatic growth restriction frequently accompanies the head-growth failure.
  evidence:
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe developmental delay/intellectual disability, severe postnatal microcephaly, often associated with growth retardation"
    explanation: Establishes microcephaly as postnatal in onset and frequently accompanied by somatic growth retardation.
  - reference: PMID:36175354
    reference_title: "Expanding the natural history of CASK-related disorders to the prenatal period."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Progressive prenatal deceleration of head circumference growth rate was observed in 15 out of 19."
    explanation: Shows that the head-growth deceleration begins prenatally in most fetuses in whom serial measurements were available.
phenotypes:
- category: Cognitive
  name: Intellectual Disability
  description: >-
    Moderate-to-severe intellectual disability is the core feature in females
    with MICPCH; hemizygous males with a null allele have severe-to-profound
    impairment. A multicentre cohort of 34 individuals graded developmental
    delay as moderate in 4, severe in 22 and profound in 8.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
    severity: SEVERE
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MICPCH is typically seen in females with moderate-to-severe intellectual disability, progressive microcephaly with or without ophthalmologic anomalies, and sensorineural hearing loss."
    explanation: GeneReviews states moderate-to-severe intellectual disability as the typical MICPCH presentation in females.
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we collected 34 patients (29 females) showing from moderate (4 patients) to severe (22) and profound (8) developmental delay"
    explanation: Quantifies the severity distribution - all 34 individuals had at least moderate impairment. The band is held at VERY_FREQUENT rather than OBLIGATE because the 100% figure comes from a clinically ascertained cohort of 34 rather than an unselected population.
- category: Developmental
  name: Global Developmental Delay
  description: >-
    Severe psychomotor delay is universal. Most affected females achieve
    independent sitting, but only 20-25% attain the ability to walk.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most are able to sit independently; 20%-25% attain the ability to walk; language is nearly absent in most."
    explanation: GeneReviews quantifies the motor and language outcome, establishing severe global developmental delay.
  - reference: PMID:22452838
    reference_title: "Spectrum of pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenotype was variable in severity but highly similar among the 11 girls and was characterized by psychomotor retardation, severe intellectual disability, progressive microcephaly, dystonia, mild dysmorphism, and scoliosis."
    explanation: Psychomotor retardation was a defining feature in all 11 girls of this series.
- category: Neurological
  name: Inability to Walk
  description: >-
    Independent ambulation is achieved by only a minority; most individuals
    remain non-ambulant, and gross motor regression has been reported in older
    individuals.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Inability to walk
    term:
      id: HP:0002540
      label: Inability to walk
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most are able to sit independently; 20%-25% attain the ability to walk"
    explanation: Only 20-25% attain walking, so 75-80% are unable to walk, which falls in the FREQUENT (30-79%) band.
- category: Neurological
  name: Absent or Severely Limited Speech
  description: >-
    Expressive language is nearly absent in most individuals with MICPCH.
  frequency: FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "language is nearly absent in most"
    explanation: GeneReviews states language is nearly absent in most affected individuals; per the project frequency-mapping guidance the word most maps to the FREQUENT band in the absence of a numerator.
- category: Neurological
  name: Progressive Microcephaly
  description: >-
    Head circumference is typically normal or near-normal at birth with
    progressive postnatal deceleration; prenatal deceleration is detectable in
    most fetuses when serial measurements are available.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Progressive microcephaly
    term:
      id: HP:0000253
      label: Progressive microcephaly
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all showed pontine and cerebellar hypoplasia, all except three with microcephaly"
    explanation: 31 of 34 individuals (91%) had microcephaly, supporting a VERY_FREQUENT band.
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of 20 patients in this study, and five previously reported patients, revealed a core clinical phenotype comprising severe developmental delay/intellectual disability, severe postnatal microcephaly, often associated with growth retardation"
    explanation: Across a 25-patient series the core phenotype includes severe postnatal microcephaly, establishing the acquired, progressive character rather than a primary congenital small head.
- category: Neurological
  name: Pontocerebellar Hypoplasia
  description: >-
    Disproportionate hypoplasia of the pons and cerebellum with a dilated fourth
    ventricle and a relatively preserved corpus callosum is the diagnostic
    imaging finding and the feature that names the disorder.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Cerebellar hypoplasia
    term:
      id: HP:0001321
      label: Cerebellar hypoplasia
  evidence:
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all showed pontine and cerebellar hypoplasia"
    explanation: All 34 individuals in this multicentre cohort had pontine and cerebellar hypoplasia. The band is held at VERY_FREQUENT rather than OBLIGATE because the cohort was ascertained partly on imaging, which inflates the apparent rate.
  - reference: PMID:23901204
    reference_title: "MICrocephaly, disproportionate pontine and cerebellar hypoplasia syndrome: A clinico-radiologic phenotype linked to calcium/calmodulin-dependent serine protein kinase gene mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "is characterized by neurodevelopmental delay, microcephaly, and disproportionate pontine and cerebellar hypoplasia"
    explanation: States the defining clinico-radiological triad of the syndrome.
- category: Neurological
  name: Hypoplasia of the Pons
  description: >-
    Brainstem hypoplasia is curated separately from the cerebellar component
    because the disproportionate involvement of the pons relative to the cerebrum
    is what distinguishes the CASK imaging signature.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypoplasia of the pons
    term:
      id: HP:0012110
      label: Hypoplasia of the pons
  evidence:
  - reference: PMID:20595373
    reference_title: "Neuroradiologic features of CASK mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a reduced area of the cerebrum, pons, midbrain, and cerebellar vermis and hemispheres"
    explanation: Quantitative morphometry documents reduced pontine area in individuals with CASK variants.
- category: Neurological
  name: Ataxia
  description: >-
    Cerebellar signs including ataxia follow from the cerebellar hypoplasia and
    granule cell loss. In the mouse model, ataxic phenotypes are the readout that
    JNK inhibition rescues, and post-adult conditional Cask deletion produces
    cerebellar degeneration with ataxia over time.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:40422253
    reference_title: "Jun N-Terminal Kinase Inhibitor Suppresses CASK Deficiency-Induced Cerebellar Granular Cell Death in MICPCH Syndrome Model Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The CASK+/- HprteGFP/+ mice exhibited cerebellar ataxic phenotypes as judged by the scores of these experiments compared to the CASK wild-type control (CASK+/+ HprteGFP/+) mice."
    explanation: The female heterozygous CASK-knockout mouse shows cerebellar ataxic phenotypes. This is model-organism evidence; human ataxia frequency in MICPCH is not separately quantified in the sources used here, which is why the band is set conservatively.
  - reference: PMID:38670634
    reference_title: "Genetic evidence for splicing-dependent structural and functional plasticity in CASK protein."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We demonstrate that deletion of murine Cask after adulthood does not affect survival but leads to cerebellar degeneration and ataxia over time."
    explanation: Post-adult conditional Cask deletion causes cerebellar degeneration and ataxia, showing an ongoing (not purely developmental) requirement for CASK in the cerebellum.
- category: Neurological
  name: Axial Hypotonia
  description: >-
    Truncal hypotonia typically coexists with hypertonia or spasticity of the
    extremities, the same dissociated tone pattern seen in several
    pontocerebellar disorders.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Axial hypotonia
    term:
      id: HP:0008936
      label: Axial hypotonia
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic features may include axial hypotonia, hypertonia/spasticity of the extremities, and dystonia or other movement disorders."
    explanation: GeneReviews lists axial hypotonia among the neurological features; the hedged wording maps to the FREQUENT band.
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "(axial) hypotonia with or without hypertonia of extremities"
    explanation: Confirms axial hypotonia as part of the core clinical phenotype defined across 25 patients.
- category: Neurological
  name: Spasticity of the Extremities
  description: >-
    Limb hypertonia and spasticity develop in a substantial proportion,
    contrasting with the axial hypotonia.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic features may include axial hypotonia, hypertonia/spasticity of the extremities, and dystonia or other movement disorders."
    explanation: GeneReviews lists hypertonia/spasticity of the extremities among the neurological features.
  - reference: PMID:35670295
    reference_title: "Pathogenic variants in CASK: Expanding the genotype-phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional findings, present in about one-third of individuals, include feeding difficulties, ophthalmologic issues, hypertonicity, epilepsy, and sensorineural hearing loss."
    explanation: Quantifies hypertonicity at about one-third of individuals, within the FREQUENT (30-79%) band.
- category: Neurological
  name: Dystonia
  description: >-
    Dystonia and other movement disorders are a recognised part of the phenotype
    and were a defining feature of the 11-girl French series.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:22452838
    reference_title: "Spectrum of pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characterized by psychomotor retardation, severe intellectual disability, progressive microcephaly, dystonia, mild dysmorphism, and scoliosis"
    explanation: Dystonia was among the features characterising all 11 girls in this series.
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "dystonia or other movement disorders"
    explanation: GeneReviews lists dystonia among the neurological features of MICPCH.
- category: Neurological
  name: Seizures
  description: >-
    Epilepsy affects roughly 40-50% of individuals and is often drug-resistant.
    Epileptic spasms are the commonest seizure type; onset is frequently in
    childhood rather than infancy and epilepsy can appear or worsen over
    follow-up, so serial monitoring is required. In the cohort where it was
    tested, epilepsy was significantly associated with intellectual disability
    severity after controlling for age.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nearly 40% have seizures by age ten years."
    explanation: GeneReviews quantifies seizure frequency at nearly 40% by age ten, within the FREQUENT (30-79%) band.
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seventeen out of 34 patients (50%) suffered from epileptic seizures, including spasms (11 patients, 32.3%), generalized (5) or focal seizures (1)."
    explanation: An independent cohort quantifies epilepsy at 50% with spasms as the commonest type, consistent with a FREQUENT band.
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Drug resistance was frequent in our cohort (52.9% of patients with epilepsy)."
    explanation: Quantifies drug resistance among those with epilepsy, informing management.
- category: Neurological
  name: Epileptic Spasms
  description: >-
    Epileptic spasms are the single commonest seizure type, and in a subset the
    EEG features and course support a diagnosis of developmental and epileptic
    encephalopathy.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Epileptic spasm
    term:
      id: HP:0011097
      label: Epileptic spasm
  evidence:
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including spasms (11 patients, 32.3%), generalized (5) or focal seizures (1)"
    explanation: Spasms occurred in 32.3% of the whole cohort, within the FREQUENT (30-79%) band.
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seven (3 males) out of the 11 children with spasms showed EEG features and a course supporting the diagnosis of a developmental and epileptic encephalopathy (DEE)."
    explanation: Documents progression to developmental and epileptic encephalopathy in the majority of those with spasms.
- category: Ophthalmological
  name: Optic Nerve Hypoplasia
  description: >-
    Optic nerve hypoplasia is part of the core phenotype; optic atrophy,
    glaucoma and megalocornea have also been reported.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Optic nerve hypoplasia
    term:
      id: HP:0000609
      label: Optic nerve hypoplasia
  evidence:
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "optic nerve hypoplasia, and/or other eye abnormalities"
    explanation: Optic nerve hypoplasia is listed within the core clinical phenotype defined across 25 patients.
  - reference: PMID:35670295
    reference_title: "Pathogenic variants in CASK: Expanding the genotype-phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional findings, present in about one-third of individuals, include feeding difficulties, ophthalmologic issues, hypertonicity, epilepsy, and sensorineural hearing loss."
    explanation: Bounds optic nerve hypoplasia from above - the broader "ophthalmologic issues" category as a whole affects about one-third, and optic nerve hypoplasia is only one member of that category, so the ONH-specific frequency must be below one-third, i.e. OCCASIONAL.
- category: Ophthalmological
  name: Optic Atrophy
  description: >-
    Optic atrophy is among the ophthalmological anomalies reported in CASK-related
    disorders, alongside glaucoma and megalocornea.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: PMID:22452838
    reference_title: "Spectrum of pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmologic anomalies (glaucoma, megalocornea and optic atrophy)"
    explanation: Lists optic atrophy among the ophthalmological anomalies frequently associated in this series.
  - reference: PMID:41039189
    reference_title: "The neurodevelopmental spectrum of CASK-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we found consistent prevalence of tone abnormalities, sensorineural hearing loss and epilepsy, but lower prevalence of severe/profound ID, MICPCH, optic atrophy and nystagmus"
    explanation: A recently diagnosed cohort found a lower prevalence of optic atrophy than earlier literature, which is why the band is set conservatively at OCCASIONAL. Caveat - this cohort spans the whole CASK-related spectrum, in which MICPCH was less prevalent than in the historical literature, so the figure is not MICPCH-specific.
- category: Ophthalmological
  name: Cerebral Visual Impairment
  description: >-
    Cerebral (cortical) visual impairment is an area of frequent difficulty
    identified in a recent systematic cohort and had not been highlighted in
    earlier reports.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cerebral visual impairment
    term:
      id: HP:0100704
      label: Cerebral visual impairment
  evidence:
  - reference: PMID:41039189
    reference_title: "The neurodevelopmental spectrum of CASK-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Areas of frequent difficulty not highlighted in previous reports include sleep difficulties and cerebral visual impairment (CVI)."
    explanation: Identifies cerebral visual impairment as an area of frequent difficulty, newly recognised relative to older reports. Caveat - this cohort spans the whole CASK-related spectrum, in which MICPCH was less prevalent than in the historical literature, so the figure is not MICPCH-specific.
- category: Auditory
  name: Sensorineural Hearing Loss
  description: >-
    Sensorineural hearing loss is a consistent part of the phenotype across both
    older and recently diagnosed cohorts.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MICPCH is typically seen in females with moderate-to-severe intellectual disability, progressive microcephaly with or without ophthalmologic anomalies, and sensorineural hearing loss."
    explanation: GeneReviews includes sensorineural hearing loss in the typical MICPCH presentation.
  - reference: PMID:41039189
    reference_title: "The neurodevelopmental spectrum of CASK-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we found consistent prevalence of tone abnormalities, sensorineural hearing loss and epilepsy"
    explanation: Confirms that sensorineural hearing loss prevalence is consistent between historical and recently diagnosed cohorts. Caveat - this cohort spans the whole CASK-related spectrum, in which MICPCH was less prevalent than in the historical literature, so the figure is not MICPCH-specific.
- category: Behavioral
  name: Sleep Disturbance
  description: >-
    Sleep disturbance is common and was identified as an area of frequent
    difficulty in a recent systematic cohort.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:41039189
    reference_title: "The neurodevelopmental spectrum of CASK-related disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Areas of frequent difficulty not highlighted in previous reports include sleep difficulties and cerebral visual impairment (CVI)."
    explanation: Identifies sleep difficulties as an area of frequent difficulty in a systematically assessed cohort. Caveat - this cohort spans the whole CASK-related spectrum, in which MICPCH was less prevalent than in the historical literature, so the figure is not MICPCH-specific.
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Behaviors may include sleep disturbances, hand stereotypies, and self biting."
    explanation: GeneReviews lists sleep disturbance among the behavioural features.
- category: Behavioral
  name: Hand Stereotypies
  description: >-
    Hand stereotypies contribute to the clinical overlap with Rett syndrome and
    other severe neurodevelopmental disorders.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Motor stereotypy
    term:
      id: HP:0000733
      label: Motor stereotypy
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Behaviors may include sleep disturbances, hand stereotypies, and self biting."
    explanation: GeneReviews lists hand stereotypies among the behavioural features; the hedged "may include" wording without a numerator supports a conservative OCCASIONAL band.
- category: Behavioral
  name: Self-Injurious Behavior
  description: >-
    Self-biting is described among the behavioural features and is a management
    concern.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Self-injurious behavior
    term:
      id: HP:0100716
      label: Self-injurious behavior
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Behaviors may include sleep disturbances, hand stereotypies, and self biting."
    explanation: GeneReviews lists self-biting among the behavioural features; the hedged wording without a numerator supports a conservative OCCASIONAL band.
- category: Gastrointestinal
  name: Feeding Difficulties
  description: >-
    Feeding difficulties affect roughly a third of individuals, often requiring
    nutritional support, and are more frequent in those with epilepsy.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:35670295
    reference_title: "Pathogenic variants in CASK: Expanding the genotype-phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional findings, present in about one-third of individuals, include feeding difficulties, ophthalmologic issues, hypertonicity, epilepsy, and sensorineural hearing loss."
    explanation: Quantifies feeding difficulties at about one-third of individuals, within the FREQUENT (30-79%) band.
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "feeding difficulties were more frequent in patients with epilepsy"
    explanation: Links feeding difficulties to the presence of epilepsy within the cohort.
- category: Growth
  name: Growth Retardation
  description: >-
    Somatic growth restriction commonly accompanies the head-growth failure.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Growth delay
    term:
      id: HP:0001510
      label: Growth delay
  evidence:
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe postnatal microcephaly, often associated with growth retardation"
    explanation: Growth retardation is described as often associated with the microcephaly in the defining phenotypic series.
- category: Skeletal
  name: Scoliosis
  description: >-
    Scoliosis is a recurrent finding, consistent with the profound axial
    hypotonia and limited ambulation.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:22452838
    reference_title: "Spectrum of pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characterized by psychomotor retardation, severe intellectual disability, progressive microcephaly, dystonia, mild dysmorphism, and scoliosis"
    explanation: Scoliosis was among the features characterising the 11 girls of this series.
- category: Craniofacial
  name: Wide Nasal Bridge
  description: >-
    A prominent and broad nasal bridge and tip with a small or short nose forms
    part of a recognisable but mild facial gestalt.
  frequency: FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Wide nasal bridge
    term:
      id: HP:0000431
      label: Wide nasal bridge
  evidence:
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A recognisable facial phenotype emerged, including prominent and broad nasal bridge and tip, small or short nose, long philtrum, small chin, and/or large ears."
    explanation: Defines the recognisable facial gestalt, of which the broad nasal bridge is the leading component.
- category: Craniofacial
  name: Long Philtrum
  description: >-
    A long philtrum is part of the recognisable facial gestalt.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Long philtrum
    term:
      id: HP:0000343
      label: Long philtrum
  evidence:
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A recognisable facial phenotype emerged, including prominent and broad nasal bridge and tip, small or short nose, long philtrum, small chin, and/or large ears."
    explanation: Long philtrum is listed as a component of the recognisable facial gestalt.
- category: Craniofacial
  name: Micrognathia
  description: >-
    A small chin is part of the recognisable facial gestalt.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Micrognathia
    term:
      id: HP:0000347
      label: Micrognathia
  evidence:
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A recognisable facial phenotype emerged, including prominent and broad nasal bridge and tip, small or short nose, long philtrum, small chin, and/or large ears."
    explanation: A small chin is listed as a component of the recognisable facial gestalt.
- category: Craniofacial
  name: Large Ears
  description: >-
    Large ears are part of the recognisable facial gestalt.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Macrotia
    term:
      id: HP:0000400
      label: Macrotia
  evidence:
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "long philtrum, small chin, and/or large ears"
    explanation: Large ears are listed as an optional ("and/or") component of the gestalt, supporting a conservative OCCASIONAL band.
genetic:
- name: CASK
  gene_term:
    preferred_term: CASK
    term:
      id: hgnc:1497
      label: CASK
  association: Causal - X-linked loss-of-function variants
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  presence: Positive
  notes: >-
    CASK is at Xp11.4. MICPCH is caused by loss-of-function alleles: whole- and
    partial-gene deletions, intragenic duplications that disrupt gene integrity,
    nonsense, frameshift and splice variants. A minority of MICPCH cases are
    caused by missense variants that specifically destroy the CASK-neurexin or
    CASK-Liprin-alpha2 interface. Hypomorphic missense and splice variants
    instead cause the milder XLID-with-or-without-nystagmus arm of the spectrum,
    which is out of scope for this entry. In males, hemizygous null alleles cause
    a severe MICPCH-plus-epileptic-encephalopathy phenotype, while mosaic or
    partly penetrant alleles give a milder picture. In a comprehensive series of
    41 individuals with a MICPCH phenotype, CASK aberrations accounted for 32
    cases, so a minority of clinically defined MICPCH is caused by other genes
    (e.g. ITPR1).
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microcephaly with pontine and cerebellar hypoplasia (MICPCH), generally associated with pathogenic loss-of-function variants in CASK. X-linked intellectual disability (XLID) with or without nystagmus, generally associated with hypomorphic CASK pathogenic variants."
    explanation: GeneReviews states the genotype-phenotype split that defines the scope of this entry - null alleles give MICPCH, hypomorphic alleles give XLID.
  - reference: PMID:28783747
    reference_title: "Comprehensive investigation of CASK mutations and other genetic etiologies in 41 patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CASK aberrations including a rare mosaic mutation in a male patient, were found in 32 cases, and a mutation in ITPR1, another known gene"
    explanation: Quantifies the CASK contribution to a clinically ascertained MICPCH series and documents locus heterogeneity.
  - reference: PMID:37628707
    reference_title: "Diverse Clinical Phenotypes of CASK-Related Disorders and Multiple Functional Domains of CASK Protein."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "missense mutations associated with epilepsy and intellectual disability were found throughout the whole region of the CASK protein, while missense mutations related to microcephaly and MICPCH were restricted in certain domains"
    explanation: Establishes a domain-level genotype-phenotype correlation - MICPCH-causing missense variants cluster in particular domains, whereas epilepsy/ID missense variants are distributed throughout the protein.
  - reference: PMID:25886057
    reference_title: "Phenotypic and molecular insights into CASK-related disorders in males."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "three phenotypic groups can be distinguished that represent a clinical continuum: (i) MICPCH with severe epileptic encephalopathy caused by hemizygous loss-of-function mutations, (ii) MICPCH associated with inactivating alterations in the mosaic state or a partly penetrant mutation, and (iii) syndromic/nonsyndromic mild to severe ID with or without nystagmus caused by CASK missense and splice mutations"
    explanation: Defines the three-group male genotype-phenotype continuum and confirms that hypomorphic missense/splice alleles map to the out-of-scope XLID arm.
diagnosis:
- name: Molecular Genetic Testing for CASK
  description: >-
    The diagnosis is established by identifying a heterozygous (female) or
    hemizygous (male) pathogenic CASK variant. Because a large fraction of
    pathogenic alleles are copy-number changes, testing must combine sequencing
    with deletion/duplication analysis (chromosomal microarray, MLPA or
    array-CGH); sequencing alone will miss them. Rarely, affected males carry the
    variant in a mosaic state, which requires appropriately sensitive testing.
  presence: Positive in affected individuals
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of a CASK disorder is established in a female who is heterozygous for a CASK pathogenic variant and in a male who is hemizygous for a CASK pathogenic variant on molecular genetic testing. Rarely, affected males have a mosaic pathogenic variant."
    explanation: GeneReviews states the molecular diagnostic criterion and flags male mosaicism.
  - reference: PMID:23901204
    reference_title: "MICrocephaly, disproportionate pontine and cerebellar hypoplasia syndrome: A clinico-radiologic phenotype linked to calcium/calmodulin-dependent serine protein kinase gene mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an array-comparative genomic hybridization (a-CGH) analysis showed CASK gene duplication at Xp11.4"
    explanation: Illustrates that copy-number analysis is required, since conventional cytogenetics was normal in this case.
- name: Brain MRI with Posterior Fossa Morphometry
  description: >-
    MRI showing disproportionate pontine and cerebellar hypoplasia with a dilated
    fourth ventricle, combined with a normal-sized corpus callosum and a low
    cerebrum/corpus callosum area ratio, is highly suggestive and distinguishes
    CASK-related pontocerebellar hypoplasia from other pontocerebellar
    hypoplasias, in which the corpus callosum is thinned.
  presence: Abnormal in essentially all affected individuals
  diagnosis_term:
    preferred_term: magnetic resonance imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  evidence:
  - reference: PMID:20595373
    reference_title: "Neuroradiologic features of CASK mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The 5 patients with pontine hypoplasia showed thinning of the corpus callosum and a high ratio of the cerebrum/corpus callosum, irrespective of the size of the cerebrum."
    explanation: Establishes the contrast with non-CASK pontine hypoplasia, in which the corpus callosum is thinned and the ratio is high.
  - reference: PMID:20595373
    reference_title: "Neuroradiologic features of CASK mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The normal size of the corpus callosum, which gives an impression of callosal thickening at first glance, may be an imaging clue to detect patients with CASK mutations."
    explanation: Identifies the specific imaging clue that should prompt CASK testing.
  - reference: PMID:21954287
    reference_title: "Phenotypic spectrum associated with CASK loss-of-function mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The combination of developmental and brain imaging features together with mild facial dysmorphism is highly suggestive of this disorder and should prompt subsequent testing of the CASK gene."
    explanation: States that the combined clinical-radiological gestalt should prompt CASK testing.
- name: Electroencephalography
  description: >-
    EEG is indicated whenever seizures, epileptic spasms, developmental
    regression or suspicious paroxysmal events occur, and it characterizes the
    epilepsy rather than merely confirming it: in a genetically confirmed CASK
    cohort the EEG showed poorly organized background activity with diffuse or
    multifocal epileptiform abnormalities and sleep activation, and in the
    majority of children with spasms the EEG features and course supported a
    diagnosis of developmental and epileptic encephalopathy. Because epilepsy
    onset is frequently in childhood and the abnormalities may appear only over
    the follow-up period, a single normal study does not exclude later epilepsy
    and serial systematic monitoring is required.
  presence: Abnormal in individuals with epilepsy, which affects roughly 40-50% of individuals
  diagnosis_term:
    preferred_term: electroencephalography
    term:
      id: NCIT:C38054
      label: Electroencephalography
  evidence:
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EEG abnormalities included poorly organized background activity with diffuse or multifocal epileptiform abnormalities and sleep-activation, with possible appearance over the follow-up period."
    explanation: Describes the characteristic EEG findings in a CASK cohort and notes that they may emerge only on follow-up, which is why the study is repeated rather than performed once.
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seven (3 males) out of the 11 children with spasms showed EEG features and a course supporting the diagnosis of a developmental and epileptic encephalopathy (DEE)."
    explanation: Shows that the EEG is what distinguishes developmental and epileptic encephalopathy from spasms alone in this disorder.
differential_diagnoses:
- name: Pontocerebellar Hypoplasia Type 2 (TSEN54)
  description: >-
    The commonest form of pontocerebellar hypoplasia and the main radiological
    differential; it is autosomal recessive and shows a thinned corpus callosum,
    whereas the corpus callosum is of normal size in CASK-related MICPCH. In one
    reference centre CASK-related PCH was the second most frequent cause of PCH.
- name: CASK-Related X-Linked Intellectual Disability With or Without Nystagmus
  description: >-
    The allelic milder arm of the CASK spectrum (FGS4/MRXSNA), caused by
    hypomorphic missense and splice variants. It typically affects males with mild
    to severe intellectual disability and nystagmus, with carrier females normal
    or mildly affected, and lacks the pontocerebellar hypoplasia. Deliberately
    curated as a distinct entity from MICPCH.
- name: Rett Syndrome (MECP2)
  description: >-
    Shares severe intellectual disability in females, acquired microcephaly, hand
    stereotypies and absent speech; distinguished by the CASK imaging signature
    and by molecular testing.
- name: ITPR1-Related Cerebellar Disorder
  description: >-
    ITPR1 variants were identified in a clinically ascertained MICPCH series and
    are part of the differential for the imaging phenotype.
- name: Congenital Disorders of Glycosylation
  description: >-
    A recognised cause of cerebellar hypoplasia with developmental delay that
    should be excluded biochemically.
treatments:
- name: Multidisciplinary Supportive Care
  description: >-
    There is no disease-modifying therapy. Treatment is symptomatic and includes
    standard management of developmental delay and intellectual disability,
    antiseizure medication, nutritional support, physiotherapy, and treatment of
    abnormal vision and hearing loss.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment is symptomatic and includes standard management of developmental delay and intellectual disability issues; medication for seizures; nutritional support; use of physiotherapy; and treatment of abnormal vision or hearing loss."
    explanation: GeneReviews defines the standard of care as symptomatic multidisciplinary management.
- name: Antiseizure Medication
  description: >-
    Seizures, most often epileptic spasms, require antiseizure treatment. Drug
    resistance is frequent, affecting over half of those with epilepsy, and
    epilepsy may appear or worsen over follow-up, so serial and systematic EEG
    and clinical monitoring is mandatory rather than optional.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Drug resistance was frequent in our cohort (52.9% of patients with epilepsy)."
    explanation: Quantifies the limited efficacy of antiseizure medication in this disorder, tempering the expected treatment benefit.
  - reference: PMID:33640666
    reference_title: "CASK related disorder: Epilepsy and developmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A childhood onset of epilepsy is frequent, with possible worsening over time, so that serial and systematic monitoring is mandatory."
    explanation: Establishes the surveillance requirement that accompanies antiseizure management.
- name: Physical Therapy and Motor Rehabilitation
  description: >-
    Physiotherapy addresses the axial hypotonia, limb hypertonia, movement
    disorder and very limited ambulation, and supports scoliosis management.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  therapeutic_modality: BEHAVIORAL
  target_phenotypes:
  - preferred_term: Axial hypotonia
    term:
      id: HP:0008936
      label: Axial hypotonia
  - preferred_term: Inability to walk
    term:
      id: HP:0002540
      label: Inability to walk
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment is symptomatic and includes standard management of developmental delay and intellectual disability issues; medication for seizures; nutritional support; use of physiotherapy; and treatment of abnormal vision or hearing loss."
    explanation: GeneReviews' statement of symptomatic management names use of physiotherapy as one component of the standard treatment package.
- name: Nutritional Support
  description: >-
    Feeding difficulties affect roughly a third of individuals and are managed
    with nutritional support, up to and including enteral feeding.
  treatment_term:
    preferred_term: nutritional support
    term:
      id: NCIT:C15433
      label: Nutritional Support
  target_phenotypes:
  - preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment is symptomatic and includes standard management of developmental delay and intellectual disability issues; medication for seizures; nutritional support; use of physiotherapy; and treatment of abnormal vision or hearing loss."
    explanation: GeneReviews' statement of symptomatic management names nutritional support as one component of the standard treatment package.
- name: Vision and Hearing Management
  description: >-
    Treatment of abnormal vision and of sensorineural hearing loss is part of
    standard care, and cerebral visual impairment specifically warrants
    assessment given its recently recognised frequency.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  - preferred_term: Cerebral visual impairment
    term:
      id: HP:0100704
      label: Cerebral visual impairment
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "treatment of abnormal vision or hearing loss"
    explanation: GeneReviews includes treatment of vision and hearing abnormalities in standard management.
- name: JNK Inhibition (Preclinical)
  description: >-
    JNK-IN-8, a Jun N-terminal kinase inhibitor, suppresses CASK-deficiency-induced
    cerebellar granule cell death in vitro by reducing reactive oxygen species,
    and intracerebellar injection suppresses granule cell death and alleviates
    ataxic phenotypes in heterozygous CASK-knockout mice. This is the only
    mechanism-directed therapeutic lead in the disorder. It is entirely
    preclinical - there are no human data, and intracerebellar delivery is not
    clinically translatable as tested.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Cerebellar Granule Cell Apoptosis via JNK/ROS Signalling
    treatment_effect: INHIBITS
    description: >-
      JNK inhibition blocks the apoptotic pathway driving cerebellar granule cell
      death, the node immediately upstream of the cerebellar hypoplasia.
  evidence:
  - reference: PMID:40422253
    reference_title: "Jun N-Terminal Kinase Inhibitor Suppresses CASK Deficiency-Induced Cerebellar Granular Cell Death in MICPCH Syndrome Model Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "JNK-IN-8 suppresses the cell death and activation of the ROS pathway in CASK-KO CG cells in both in vitro and in vivo models, suggesting its potential as a therapeutic strategy for cerebellar neurodegeneration in MICPCH syndrome."
    explanation: Establishes JNK inhibition as a preclinical therapeutic strategy; the evidence is entirely from mouse and cell models.
- name: Genetic Counseling
  description: >-
    Counselling covers X-linked inheritance, the predominance of de novo variants,
    the point that an asymptomatic mother is unlikely to be a heterozygote because
    heterozygous females manifest the disorder, the possibility of parental
    germline mosaicism, and prenatal/preimplantation testing once a familial
    variant is known.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Risk to the family members of a proband with a CASK disorder depends on the phenotype (i.e., MICPCH or XLID ± nystagmus) in the proband."
    explanation: GeneReviews states that recurrence-risk counselling is phenotype-dependent within the CASK spectrum.
animal_models:
- species: Mouse
  genotype: CASK heterozygous knockout (CASK+/-) female, with X-linked GFP reporter
  genes:
  - preferred_term: CASK
    term:
      id: hgnc:1497
      label: CASK
  associated_phenotypes:
  - Cerebellar hypoplasia
  - Motor deficits
  description: >-
    Female heterozygous CASK-knockout mice replicate the progressive cerebellar
    hypoplasia and motor deficits of MICPCH. Combined with an X-linked GFP
    reporter they allow direct visualisation of the CASK-positive/CASK-negative
    mosaic and of the selective postnatal elimination of the CASK-negative
    population.
  evidence:
  - reference: PMID:40422238
    reference_title: "The Competitive Loss of Cerebellar Granule and Purkinje Cells Driven by X-Linked Mosaicism in a Female Mouse Model of CASK-Related Disorders."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The CASK-hKO mice exhibited motor deficits and cerebellar hypoplasia similar to those observed in patients with CASK-related disorders."
    explanation: Establishes face validity of the female heterozygous knockout mouse for the human cerebellar and motor phenotype.
  - reference: PMID:37190086
    reference_title: "Structural Analysis Implicates CASK-Liprin-α2 Interaction in Cerebellar Granular Cell Death in MICPCH Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Female CASK heterozygote KO mice replicate the progressive cerebellar hypoplasia observed in MICPCH syndrome."
    explanation: Independently confirms that the female heterozygous knockout reproduces the progressive cerebellar hypoplasia.
discussions:
- discussion_id: micpch_cask_molecular_function_mapping
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Which of CASK's several molecular functions actually accounts for the MICPCH
    brain phenotype, and does the relationship between CASK molecular function and
    tissue pathology in model organisms translate to human disease?
  attaches_to:
  - pathophysiology#Disrupted CASK-Neurexin Presynaptic Scaffold Interaction
  - pathophysiology#Disrupted CASK-Liprin-alpha2 Interaction via the CaMK Domain
  rationale: >-
    CASK is a multidomain scaffold with many binding partners, and the literature
    has successively implicated the CASK-TBR1 transcriptional interface, the
    CASK-neurexin presynaptic interface and the CASK-Liprin-alpha2 interface. The
    investigators who built and characterised the MICPCH mouse models explicitly
    warn that the relationship between CASK molecular function and the phenotypes
    observed in model organisms and humans is highly complex and should not be
    oversimplified. The two molecular nodes curated here are therefore both
    retained rather than collapsed, and neither is asserted as the sole mechanism.
    Resolving this matters because a mechanism-directed therapy has to target the
    right interface.
  proposed_experiments:
  - experiment_id: micpch_interface_specific_knockin
    name: Interface-specific Cask knock-in mouse allelic series
    description: >-
      Generate mice carrying separation-of-function Cask alleles that
      independently disrupt the neurexin, Liprin-alpha2 and TBR1 interfaces, and
      compare cerebellar granule cell survival, cerebellar volume and behaviour.
    decision_criterion: >-
      If only one interface allele reproduces cerebellar hypoplasia, that
      interface is the causal one; if several do, the mechanism is combinatorial.
  - experiment_id: micpch_patient_organoid_interface
    name: Patient-derived cerebellar organoid interface rescue
    description: >-
      Rescue CASK-null human cerebellar organoids with CASK constructs selectively
      defective for each interface and measure granule cell survival.
    decision_criterion: >-
      Failure of a given construct to rescue identifies its interface as required
      in human tissue, addressing the model-to-human translation gap directly.
  evidence:
  - reference: PMID:35406695
    reference_title: "The Non-Linear Path from Gene Dysfunction to Genetic Disease: Lessons from the MICPCH Mouse Model."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Our studies point to a highly complex relationship between the potential molecular function/s of CASK and the phenotypes observed in model organisms and humans."
    explanation: Expert perspective from the authors of the MICPCH mouse work, explicitly cautioning against a simple molecular-function-to-phenotype mapping; this is the substance of the open question, and is tagged OTHER because the source is a review rather than primary data.
  - reference: PMID:35406695
    reference_title: "The Non-Linear Path from Gene Dysfunction to Genetic Disease: Lessons from the MICPCH Mouse Model."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Here we discuss the implications of our observations from the pathogenesis of MICPCH as a cautionary narrative against oversimplifying molecular interpretations of data obtained from genetically modified animal models of human diseases."
    explanation: Framing sentence of a review stating the translational-validity caveat that motivates classifying this as HUMAN_MODEL_MISMATCH; curated as PARTIAL/OTHER because it declares a position rather than reporting a result.

📚

References & Deep Research

References

1

PMID:24278995

CASK Disorders.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 24 citations 2026-07-31T17:29:47.692541

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: MICPCH Syndrome
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on MICPCH Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

MICPCH syndrome: disease-characteristics research report

Executive summary

Microcephaly with pontine and cerebellar hypoplasia (MICPCH) is a rare, usually de novo X-linked neurodevelopmental disorder caused principally by loss-of-function variants or deletions involving CASK at Xp11.4. The characteristic course in females is normal or near-normal head size at birth, developmental delay emerging during infancy, progressive postnatal microcephaly, severe intellectual and motor disability, and disproportionate pontine/cerebellar hypoplasia. Hemizygous males generally have a much more severe epileptic encephalopathy; surviving less-severely affected males often have hypomorphic or mosaic variants. No disease-modifying therapy or registered interventional trial was identified; present implementation is molecular diagnosis, genetic counseling, and multidisciplinary supportive care. Recent 2023–2024 work emphasizes that CASK disease is mechanistically heterogeneous, involving splice-dependent protein functions, selective cerebellar granule-cell degeneration, and altered synaptic excitation/inhibition rather than one simple developmental pathway. (mukherjee2022thenonlinearpath pages 2-3, mori2023diverseclinicalphenotypes pages 2-5, patel2024geneticevidencefor pages 1-3)

Domain	Key findings	Ontology / identifier suggestions	Key statistics / notes	Evidence
Definition / identifiers	MICPCH = microcephaly with pontine and cerebellar hypoplasia; rare X-linked neurodevelopmental disorder within the CASK-related disorder spectrum, usually defined at disease level from aggregated resources plus patient-level case/cohort reports. OMIM explicitly cited as 300749 in recent literature.	OMIM: 300749; Gene: CASK; disease label: microcephaly with pontine and cerebellar hypoplasia syndrome	2023 review summarized 49 reports and 197 patients across CASK-related disorders.	(zhang2022adenovo pages 7-10, mori2023diverseclinicalphenotypes pages 2-5)
Cause / inheritance	Primary cause is loss-of-function or hypomorphic pathogenic variants in CASK on Xp11.4; includes nonsense, frameshift/indel, splice, missense, and copy-number loss. Inheritance is usually de novo X-linked dominant in females; hemizygous males are often much more severely affected, and somatic mosaicism can permit survival with milder disease in males.	HGNC gene suggestion: CASK; inheritance: X-linked dominant / X-linked semidominant; variant consequence: loss of function	In 41-patient MICPCH cohort, causative/candidate aberrations in 37/41 (90.2%); 32/41 involved CASK, including 23 point mutations and 9 CNVs.	(hayashi2017comprehensiveinvestigationof pages 2-3, hayashi2017comprehensiveinvestigationof pages 1-2, hayashi2017comprehensiveinvestigationof pages 4-6)
Hallmark phenotypes and frequencies	Core phenotype: severe developmental delay/intellectual disability, postnatal progressive microcephaly, hypotonia or motor disorder, and pontocerebellar hypoplasia. Additional features can include dystonia, scoliosis, epilepsy, ophthalmologic abnormalities, hearing loss, growth retardation, and feeding difficulties. Suggested HPO terms: Microcephaly (HP:0000252), Progressive microcephaly (HP:0000253), Cerebellar hypoplasia (HP:0001321), Pontine hypoplasia (HP:0007366), Global developmental delay (HP:0001263), Severe intellectual disability (HP:0010864), Seizure (HP:0001250), Hypotonia (HP:0001252), Dystonia (HP:0001332), Sensorineural hearing impairment (HP:0000407), Optic atrophy/hypoplasia (HP:0000648/HP:0008058), Feeding difficulties (HP:0011968), Scoliosis (HP:0002650).	HPO terms as listed	Burglen 2012: 13/14 screened PCH patients had CASK abnormalities; in those 13, epilepsy in 4/13, hearing loss in 2/13; severe microcephaly < -6 SD in 7, -3 to -4 SD in 4. Hayashi 2017: only 6/41 could walk and 3/41 could speak. Review-level estimate: seizures occur in about 40% of cases.	(mukherjee2022thenonlinearpath pages 2-3, burglen2012spectrumofpontocerebellar pages 7-9, hayashi2017comprehensiveinvestigationof pages 2-3)
MRI / neuroradiology	Typical MRI shows pontine and cerebellar hypoplasia, often with variable vermian and hemispheric involvement and relative preservation of supratentorial structures compared with classic neurodegenerative PCH. Corpus callosum is often normal or relatively spared; a low brain-to-corpus-callosum ratio has been suggested as a clue to CASK-related disease.	UBERON suggestions: cerebellum (UBERON:0002037), pons (UBERON:0000988), corpus callosum (UBERON:0000955), brainstem (UBERON:0002298)	van Dijk 2021 included 6 MICPCH patients and found severe cerebellar hypoplasia at birth with nearly absent postnatal growth, but without the caudate/ventricular changes seen in PCH1B/PCH2A. Burglen 2012 found universal brainstem/cerebellar hypoplasia in affected individuals.	(burglen2012spectrumofpontocerebellar pages 7-9, zhang2022adenovo pages 7-10)
Diagnosis	Diagnosis is clinical-radiologic plus molecular: suspect in infants/children, especially females, with postnatal progressive microcephaly, severe developmental delay, and PCH-like MRI. Recommended testing emphasizes broad genomic testing (WES/WGS or neurodevelopmental/PCH panels) plus CNV analysis because both sequence variants and deletions occur. Differential diagnosis includes other genetic causes of radiologic PCH and non-CASK monogenic/chromosomal etiologies.	Diagnostic concepts: WES, WGS, CNV analysis, multigene panel; HPO-driven genomic analysis	Hayashi 2017 showed high yield with combined genomic investigation: 37/41 (90.2%) solved/candidate; Zakaria 2024 emphasized broad testing because classic OMIM-listed PCH genes explain only a minority of radiologic PCH cases.	(hayashi2017comprehensiveinvestigationof pages 2-3, hayashi2017comprehensiveinvestigationof pages 1-2)
Mechanism / pathophysiology	CASK is a MAGUK scaffold protein with CaMK, L27, PDZ, SH3, and GuK domains and roles in synaptic organization, protein interactions, and nuclear transcriptional regulation (including TBR1/CINAP-related pathways affecting GRIN2B/GluN2B and RELN). Human and mouse evidence supports a mixed mechanism: developmental hindbrain malformation plus post-developmental cerebellar granule-cell vulnerability/degeneration; neuronal CASK deficiency can also disrupt excitatory/inhibitory synaptic balance via GluN2B downregulation, and metabolic stress/oxidative metabolism defects may contribute. Suggested GO terms: synapse organization, regulation of excitatory postsynaptic potential, cerebellar granule cell development/survival, regulation of gene expression, cellular respiration. Suggested CL terms: cerebellar granule cell, Purkinje cell, cortical pyramidal neuron, astrocyte.	GO / CL suggestions as listed; cellular compartments: synapse, nucleus, cytoplasm	Mori 2019 showed GluN2B rescue corrected E/I imbalance in CASK-deficient neurons. Srivastava 2016 suggested non-cell-autonomous postnatal brain growth effects and metabolic abnormalities. Patel 2024 supports splice-dependent forebrain vs hindbrain functional differences.	(patel2024geneticevidencefor pages 1-3, patel2024geneticevidencefor pages 9-11, mori2019deficiencyofcalciumcalmodulindependent pages 1-2, patel2024geneticevidencefor pages 3-4, patel2024geneticevidencefor pages 14-16, patel2024geneticevidencefor pages 11-12)
Management / real-world care	No disease-modifying therapy is established. Current care is supportive and multidisciplinary: developmental therapies, nutritional/feeding support, seizure management, audiology/hearing support, ophthalmology, orthopedic monitoring for scoliosis, and genetic counseling.	NCIT suggestions: Supportive Care, Physical Therapy, Occupational Therapy, Speech Therapy, Anticonvulsant Therapy, Gastrostomy, Hearing Aid Device, Genetic Counseling	Clinical-trial search identified no relevant interventional MICPCH/CASK trials in available tool output. Preclinical concepts (e.g., targeting GluN2B pathways or metabolic dysfunction) remain experimental, not standard care.	(mukherjee2022thenonlinearpath pages 2-3, mori2019deficiencyofcalciumcalmodulindependent pages 1-2, patel2024geneticevidencefor pages 3-4)
Prognosis / outcomes	Prognosis is dominated by lifelong severe neurodevelopmental impairment. Females often have a non-progressive or slowly evolving developmental encephalopathy after early postnatal decline in head growth, whereas hemizygous males may have profound encephalopathy, refractory epilepsy, and respiratory/swallowing complications. Functional outcomes are commonly poor, with major limitations in ambulation and speech.	Outcome concepts: severe developmental disability, epilepsy, feeding impairment	Hayashi 2017: 6/41 walked and 3/41 spoke. Burglen 2012 described a severely affected hemizygous boy with refractory epilepsy and a milder mosaic male. Robust disease-specific life expectancy statistics are not available from the retrieved evidence.	(mukherjee2022thenonlinearpath pages 2-3, burglen2012spectrumofpontocerebellar pages 7-9, hayashi2017comprehensiveinvestigationof pages 2-3)
Evidence gaps	Major gaps remain in prevalence/incidence, penetrance estimates, genotype-specific prognosis, quality-of-life metrics, validated biomarkers, standardized treatment algorithms, and controlled therapeutic studies. Recent mechanistic work is largely preclinical, and direct human multi-omics or longitudinal natural-history datasets are limited.	Data gap annotation; future ontology mapping could add MONDO/Orphanet when confirmed from source databases	No reliable population prevalence, carrier frequency, or survival curves were found in the retrieved evidence; no established preventive medical intervention beyond reproductive genetic counseling/testing.	(hayashi2017comprehensiveinvestigationof pages 2-3, mori2023diverseclinicalphenotypes pages 2-5, patel2024geneticevidencefor pages 1-3)

Table: This compact table summarizes the core knowledge-base elements for MICPCH syndrome, including definition, genetics, phenotype, imaging, diagnosis, mechanism, management, prognosis, and current evidence gaps. It highlights study-level statistics and ontology suggestions while staying within the available evidence.

1. Disease information

Definition. MICPCH is the severe structural-neurodevelopmental end of the CASK-related disorder spectrum. “Pontocerebellar hypoplasia” describes reduced pons and cerebellar volume on imaging; unlike several classic PCH syndromes, CASK-associated disease is not adequately characterized as a uniformly progressive prenatal neurodegeneration. Relative supratentorial preservation and lack of the caudate/ventricular evolution seen in PCH1B/PCH2A support a distinct pathogenesis. (burglen2012spectrumofpontocerebellar pages 7-9, zhang2022adenovo pages 7-10)

Identifiers and names. Confirmed in the retrieved literature: OMIM 300749. Common names include microcephaly with pontine and cerebellar hypoplasia, MICPCH syndrome, CASK-related MICPCH, and historically mental retardation and microcephaly with pontine and cerebellar hypoplasia. The broader category is CASK-related disorder. A MONDO identifier, Orphanet number, dedicated MeSH heading, and disease-specific ICD-10/ICD-11 code were not verified in the retrieved primary texts and should be validated directly against current ontology releases rather than inferred. Clinically, cases are usually coded under manifestations such as congenital brain malformation, microcephaly, developmental disorder, or epilepsy.

Evidence provenance. This entry combines aggregated disease-level interpretation with individual case reports and referral cohorts. The strongest patient-level datasets retrieved were Burglen et al. (13 molecularly affected patients) and Hayashi et al. (41 patients ascertained by microcephaly plus PCH on MRI). These are not population registries and therefore cannot provide unbiased prevalence or penetrance estimates. (burglen2012spectrumofpontocerebellar pages 7-9, hayashi2017comprehensiveinvestigationof pages 2-3)

2. Etiology, risk, protection, and gene–environment interaction

The primary causal factor is a germline or postzygotic pathogenic CASK variant causing complete or partial loss of function. Established classes include nonsense, frameshift/indel, splice-altering, deleterious missense and in-frame variants, intragenic copy-number changes, and larger Xp11.4 deletions. In the 41-patient cohort, 32 had CASK abnormalities—23 point variants and nine CNVs—while five had candidate abnormalities involving other genes, demonstrating that the radioclinical MICPCH phenotype is genetically heterogeneous even though CASK is its dominant cause. (hayashi2017comprehensiveinvestigationof pages 2-3, hayashi2017comprehensiveinvestigationof pages 1-2, hayashi2017comprehensiveinvestigationof pages 4-6)

Risk is principally genetic: female heterozygosity, male hemizygosity, postzygotic mosaicism, or rarely inheritance from a carrier/mosaic parent. Most confirmed cases are de novo. Male hemizygous complete loss is associated with profound disease or early lethality; mosaicism preserves a population of CASK-expressing cells and can produce a female-like or milder phenotype. Random X-chromosome inactivation creates cellular mosaicism in females and is a plausible contributor to variability, although routine blood X-inactivation measurements do not reliably predict neurological severity. (mukherjee2022thenonlinearpath pages 2-3, burglen2012spectrumofpontocerebellar pages 7-9, hayashi2017comprehensiveinvestigationof pages 1-2)

No reproducible environmental, lifestyle, infectious, occupational, or toxic risk factors are established. Likewise, no validated protective genetic alleles, diets, exposures, or gene–environment interactions are known. Metabolic state may modulate cellular vulnerability in experimental systems, but this is not evidence for a modifiable human environmental risk. Consanguinity and anticipation are not expected drivers of this predominantly de novo X-linked disorder. (patel2024geneticevidencefor pages 3-4)

3. Phenotypes

The hallmark phenotype is severe, early-onset neurodevelopmental disability. In Hayashi’s 41-patient imaging-defined cohort, only 6/41 walked and 3/41 spoke, indicating profound effects on mobility, communication, self-care, education, and caregiver burden. No MICPCH-specific EQ-5D, SF-36, PROMIS, or validated quality-of-life series was found. (hayashi2017comprehensiveinvestigationof pages 2-3)

Progressive postnatal microcephaly: often normal head circumference at birth, followed by deceleration during infancy; severe and usually persistent. Burglen reported head circumference below −6 SD in seven patients and −3 to −4 SD in four. Suggested HPO: Microcephaly HP:0000252, Progressive microcephaly HP:0000253. (mukherjee2022thenonlinearpath pages 2-3, burglen2012spectrumofpontocerebellar pages 7-9)
Global developmental delay/severe intellectual disability: generally apparent by 3–6 months and lifelong; expressive language and independent ambulation are especially limited. HPO: Global developmental delay HP:0001263, Severe intellectual disability HP:0010864, Delayed speech and language development HP:0000750, Motor delay HP:0001270. (mukherjee2022thenonlinearpath pages 2-3, hayashi2017comprehensiveinvestigationof pages 2-3)
Pontine and cerebellar hypoplasia: congenital/infantile imaging sign with variable vermian and hemispheric severity; postnatal cerebellar growth may be nearly absent. HPO: Pontine hypoplasia HP:0007366, Cerebellar hypoplasia HP:0001321, Vermis hypoplasia HP:0001320. (burglen2012spectrumofpontocerebellar pages 7-9)
Tone and movement abnormalities: axial hypotonia is common early; dystonia, spasticity or mixed motor impairment may develop. Severity is variable but often function-limiting. HPO: Hypotonia HP:0001252, Dystonia HP:0001332, Spasticity HP:0001257, Ataxia HP:0001251. (burglen2012spectrumofpontocerebellar pages 7-9, zhang2022adenovo pages 7-10)
Epilepsy: variable in females but more frequent and severe in males; approximately 40% is cited in a recent disease review. Phenotypes include infantile spasms/West syndrome, Ohtahara syndrome and refractory developmental epileptic encephalopathy. Burglen observed epilepsy in 4/13, one refractory. HPO: Seizure HP:0001250, Infantile spasms HP:0012469. (mukherjee2022thenonlinearpath pages 2-3, burglen2012spectrumofpontocerebellar pages 7-9)
Feeding and respiratory dysfunction: neonatal feeding difficulty occurred throughout the Burglen cohort; severe males may have dysphagia and central neurogenic respiratory failure associated with brainstem thinning. HPO: Feeding difficulties HP:0011968, Dysphagia HP:0002015, Central hypoventilation HP:0007110. (mukherjee2022thenonlinearpath pages 2-3, burglen2012spectrumofpontocerebellar pages 7-9)
Ophthalmologic disease: optic-nerve hypoplasia/atrophy, nystagmus, strabismus, megalocornea or glaucoma are reported. HPO: Optic nerve hypoplasia HP:0000609, Optic atrophy HP:0000648, Nystagmus HP:0000639, Glaucoma HP:0000501. At least six of Burglen’s 13 had ophthalmologic abnormalities. (burglen2012spectrumofpontocerebellar pages 7-9)
Hearing impairment: sensorineural loss is recognized but not universal; Burglen reported 2/13. HPO: Sensorineural hearing impairment HP:0000407. (burglen2012spectrumofpontocerebellar pages 7-9)
Growth, skeletal and craniofacial findings: postnatal growth retardation, scoliosis, micrognathia, prominent ears, long philtrum and characteristic but nonspecific facial appearance. HPO: Growth delay HP:0001510, Scoliosis HP:0002650, Micrognathia HP:0000347. (burglen2012spectrumofpontocerebellar pages 7-9, zhang2022adenovo pages 7-10)

4. Genetic and molecular information

Causal gene. CASK encodes an X-linked membrane-associated guanylate kinase scaffold expressed strongly in the nervous system. The protein contains CaMK-like, L27, PDZ, SH3 and guanylate-kinase-like domains. Its PDZ domain binds neurexins/syndecans, SH3-related interactions include N-type calcium-channel machinery, and the GuK domain interacts with TBR1 and CINAP in nuclear transcriptional complexes regulating genes such as GRIN2B and RELN. (mori2023diverseclinicalphenotypes pages 2-5)

Variants. The 2023 review surveyed 49 reports/197 patients and noted 306 ClinVar variants: 37 frameshift, 227 missense and 43 nonsense records; truncating variants were much more often pathogenic/likely pathogenic and associated with more severe phenotypes than missense variants (p<0.0001). These database counts are not disease prevalence or carrier-frequency estimates. Representative pathogenic variants in Hayashi included c.79C>T (p.Arg27Ter), c.316C>T (p.Arg106Ter), c.868G>T (p.Glu290Ter), c.2632C>T (p.Gln878Ter), and frameshift/stop variants such as c.1006_1012del (p.Thr336GlnfsTer23). (mori2023diverseclinicalphenotypes pages 2-5, hayashi2017comprehensiveinvestigationof pages 4-6)

Most severe MICPCH variants act through loss of function—nonsense-mediated decay, absent/truncated protein, destabilization, or gene dosage loss. A reported c.638T>G missense variant reduced protein but not mRNA, consistent with protein destabilization. No recurrent hotspot explains most cases, and variant size alone does not reliably predict phenotype. (zhang2022adenovo pages 7-10)

Variants are normally germline; mosaic variants are postzygotic, not neoplastic “somatic mutations.” Population allele frequencies are expected to be absent or extremely low for pathogenic alleles, but variant-specific gnomAD/TOPMed values must be retrieved by genomic coordinate and transcript and were not available in the gathered texts. No validated modifier gene or protective allele is established. Larger Xp11.4 deletions may introduce contiguous-gene effects. No disease-specific DNA-methylation episignature or causal epigenetic lesion is established.

A major 2024 development is splice-dependent functional plasticity. Vertebrate-specific exons 19–20 encode a flexible loop between PDZ and SH3 regions; isoforms that include or exclude these exons differ structurally. Damaging variants confined to these exons can preserve older CASK isoforms and produce microcephaly/forebrain dysfunction without classic PCH, helping explain non-linear genotype–phenotype relationships. (patel2024geneticevidencefor pages 1-3, patel2024geneticevidencefor pages 9-11)

5. Environmental information

There is no evidence that toxins, radiation, pollution, smoking, alcohol, diet, exercise, occupation, or infection causes MICPCH. Pregnancy is often reportedly uncomplicated. These exposures can independently affect fetal development and should be evaluated in the differential diagnosis, but they are not established components of CASK-MICPCH etiology. No pathogen or zoonotic transmission is applicable.

6. Mechanism and pathophysiology

A defensible causal chain is:

pathogenic CASK variant/CASK haploinsufficiency → altered scaffold, transcriptional and metabolic functions → selective neuronal and circuit vulnerability → impaired hindbrain growth plus cerebellar granule-cell loss and synaptic E/I imbalance → pontocerebellar hypoplasia, progressive microcephaly, epilepsy and severe developmental disability.

Upstream events are reduced CASK dosage, destabilized protein, or splice-isoform disruption. Intermediate mechanisms include impaired protein interactions at synapses, altered TBR1/CINAP-linked transcription, reduced GluN2B, mitochondrial/oxidative-metabolic disturbance, and non-cell-autonomous growth effects. Downstream consequences are granule-cell degeneration, circuit imbalance, seizures, poor motor learning and reduced brain growth. These mechanisms are complementary hypotheses rather than one fully validated human pathway. (patel2024geneticevidencefor pages 1-3, mori2019deficiencyofcalciumcalmodulindependent pages 1-2, patel2024geneticevidencefor pages 3-4)

In mouse brain slices, CASK-deficient pyramidal neurons showed increased miniature excitatory and decreased inhibitory postsynaptic currents. GluN2B overexpression rescued the E/I imbalance, making GRIN2B downregulation a mechanistically strong preclinical finding, although not yet a proven therapeutic target in patients. Suggested GO terms: synapse organization, chemical synaptic transmission, regulation of excitatory postsynaptic potential, regulation of inhibitory postsynaptic potential, and NMDA-receptor signaling. Suggested cell type: cortical pyramidal neuron. (mori2019deficiencyofcalciumcalmodulindependent pages 1-2)

Cerebellar granule cells appear particularly CASK-dependent. Conditional deletion after adulthood caused progressive cerebellar degeneration and ataxia without reducing survival, arguing that apparent “hypoplasia” can include post-migratory degeneration. Conversely, selective loss of exon 19–20-containing isoforms can spare cerebellum while affecting forebrain function. Suggested GO terms: cerebellar granule-cell differentiation/survival, neuron death, cerebellar development; CL suggestions: cerebellar granule cell, Purkinje cell, astrocyte. (patel2024geneticevidencefor pages 1-3, patel2024geneticevidencefor pages 9-11, patel2024geneticevidencefor pages 14-16)

Human-cell knockdown and heterozygous mouse work implicated reduced cellular respiration and abnormal brain/muscle oxidative metabolism. This supports metabolic stress as a possible contributor, but no validated patient metabolomic biomarker or metabolic treatment exists. Immune activation is not a primary mechanism; astrogliosis in severe cerebellar pathology is better interpreted as a downstream response to neuronal injury. (patel2024geneticevidencefor pages 3-4)

No disease-specific single-cell atlas, spatial-transcriptomic dataset, clinical proteomic/metabolomic signature, or integrated patient multi-omics classifier was identified. Current advanced work is mainly conditional genome editing in mice, RT-PCR of isoforms, electrophysiology and in-silico/structural modeling. (patel2024geneticevidencefor pages 1-3, patel2024geneticevidencefor pages 9-11)

7. Anatomical structures affected

The central nervous system is primary. Core structures are the cerebellar hemispheres and vermis (UBERON:0002037, cerebellum), pons (UBERON:0000988) and brainstem (UBERON:0002298). The superior pons may be relatively spared, and the corpus callosum is often preserved or proportionate, although variable cerebral and callosal abnormalities occur. Findings are generally bilateral, but cerebellar hemispheric asymmetry has been described. (burglen2012spectrumofpontocerebellar pages 7-9, hayashi2017comprehensiveinvestigationof pages 4-6)

At tissue/cell level, nervous tissue and especially cerebellar granule neurons are implicated; cortical pyramidal neurons show circuit dysfunction in models, and astrocytes participate in reactive gliosis. Secondary systems include optic nerve/retina, auditory pathways, axial musculature, skeleton and oropharyngeal/respiratory motor systems. Subcellular localization spans synaptic membranes and protein complexes, cytoplasm, nucleus/transcriptional complexes, and potentially mitochondria/metabolic machinery. Relevant GO cellular-component suggestions include synapse, postsynaptic density, presynaptic active zone, cytoplasm and nucleus. (mori2023diverseclinicalphenotypes pages 2-5, mori2019deficiencyofcalciumcalmodulindependent pages 1-2, patel2024geneticevidencefor pages 3-4)

8. Temporal development

Onset is congenital-to-infantile but often insidious. Many girls have normal head size at birth; motor delay becomes evident at approximately 3–6 months, followed by progressive postnatal microcephaly and recognition of PCH on infant MRI. Cerebellum can already be severely small at birth and show little subsequent growth. (mukherjee2022thenonlinearpath pages 2-3)

The course is chronic and lifelong. In heterozygous females, early structural/growth pathology is often described as self-limiting or relatively non-progressive rather than continuously degenerative, although developmental gains remain markedly impaired and late regression/ataxia has occasionally been reported. Complete male loss permits more severe ongoing degeneration, early epileptic encephalopathy, swallowing/respiratory failure and early death. Adult conditional mouse deletion demonstrates that CASK remains necessary for cerebellar maintenance, but the extent of analogous late human progression is uncertain. (mukherjee2022thenonlinearpath pages 2-3, patel2024geneticevidencefor pages 1-3)

There are no validated clinical stages, remission pattern, or therapeutic critical window. Infancy is biologically and clinically important because head-growth deceleration, seizures, feeding difficulty and developmental delay emerge then, and early supportive intervention is most feasible.

9. Inheritance and population

Inheritance is best described as X-linked dominant/semidominant with sex-dependent severity. Most typical affected females have a de novo heterozygous variant. Hemizygous male loss-of-function variants cause severe encephalopathy or lethality; hypomorphic or postzygotic mosaic variants can be survivable. In Burglen, all molecular findings were de novo, including the first described mildly affected mosaic male. (burglen2012spectrumofpontocerebellar pages 7-9)

Penetrance for unequivocal loss-of-function variants appears high, but formal age- and sex-stratified estimates are unavailable. Expressivity is variable and influenced by residual function, mosaicism, variant domain/splicing, and probably X-inactivation. Germline mosaicism remains a counseling consideration even when parental blood testing is negative; recurrence risk is therefore low but not zero. Anticipation, founder effects and population-specific high-frequency alleles are not established.

No reliable incidence, prevalence per 100,000, carrier frequency, geographic concentration, or ethnic enrichment was found. Referral cohorts are female-skewed: Hayashi included 35 females and six males. This reflects biological ascertainment—typical MICPCH is predominantly female and complete male loss is much more severe—not evidence of geographic restriction. (hayashi2017comprehensiveinvestigationof pages 2-3, hayashi2017comprehensiveinvestigationof pages 1-2)

10. Diagnostics

Diagnosis requires a compatible phenotype plus molecular confirmation. Clinical evaluation includes serial head circumference and growth, developmental/neurologic examination, feeding and respiratory assessment, ophthalmology, audiology, and musculoskeletal evaluation. Brain MRI is preferred over CT and should evaluate pons, vermis, cerebellar hemispheres, supratentorial structures, corpus callosum and optic pathways. EEG is indicated for seizures, spasms, regression or suspicious events; hearing testing and visual evoked/ophthalmic studies are individualized. There is no diagnostic blood enzyme, metabolite, protein biomarker, biopsy or histopathology requirement.

Testing algorithm:

Trio exome or genome sequencing with CNV calling, or a comprehensive neurodevelopmental/PCH panel including CASK.
Ensure deletion/duplication analysis—sequence-only testing can miss intragenic or Xp11.4 CNVs.
Confirm by orthogonal sequencing/CNV method and test parents.
In an affected male with negative blood testing or discordant severity, use high-depth testing for mosaicism and consider a second tissue.
If negative, reassess the radiologic label and investigate other PCH/cerebellar-development genes and chromosomal causes.

Combined genomic investigation identified causative/candidate abnormalities in 37/41 (90.2%) in a selected MRI-defined cohort; this is not a general-population diagnostic yield. WES is particularly useful, but WGS may better detect noncoding, structural and mosaic variants. CMA is useful for deletions; karyotyping and FISH are not first-line unless a larger rearrangement is suspected. Mitochondrial DNA and repeat-expansion testing are not routine unless additional features suggest another disorder. (hayashi2017comprehensiveinvestigationof pages 2-3, zhang2022adenovo pages 7-10)

Differential diagnoses include TSEN54/PCH2 and other classic PCH disorders; ITPR1- or RELN-related cerebellar disease; DDX3X-, PNKP- and other microcephaly-developmental disorders; chromosomal CNVs; congenital infection; and acquired prenatal/perinatal injury. Preserved supratentorial structures/corpus callosum, postnatal microcephaly, female sex and a CASK variant favor MICPCH. Broad testing is important because radiologic PCH is an imaging descriptor rather than a single etiologic class. (hayashi2017comprehensiveinvestigationof pages 1-2, hayashi2017comprehensiveinvestigationof pages 4-6)

There is no population newborn screen. Cascade testing is appropriate after a familial variant is found; prenatal and preimplantation testing are technically feasible for a known pathogenic variant.

11. Outcome and prognosis

No robust 5- or 10-year survival rates, life-expectancy curves, disease-specific mortality rates or validated prognostic biomarkers are available. Female survival into adulthood occurs, but severe lifelong disability is common. Functional prognosis is poor: in the 41-patient cohort, only 14.6% walked and 7.3% spoke. Male prognosis depends strongly on residual CASK function/mosaicism; complete loss is associated with refractory epilepsy, profound developmental impairment, respiratory/swallowing complications and possible early death. (mukherjee2022thenonlinearpath pages 2-3, hayashi2017comprehensiveinvestigationof pages 2-3)

Morbidity includes nonverbal or minimally verbal communication, non-ambulation, feeding dependence, epilepsy, visual/hearing impairment, scoliosis and extensive caregiver needs. Recovery to normal development is not expected, although therapies may improve comfort, communication, mobility and participation. Likely prognostic features include sex, mosaic allele fraction, residual protein function, seizure burden, respiratory/feeding involvement and severity of cerebellar/brainstem disease; none forms a validated prediction model.

12. Treatment and implementation

There is no established disease-modifying pharmacotherapy, gene therapy, RNA therapy or cell therapy. A ClinicalTrials.gov search for MICPCH/CASK-related disease identified no relevant interventional trial. Present management is individualized and multidisciplinary:

antiseizure medication selected by seizure type and EEG syndrome; rescue plans for prolonged seizures;
physical and occupational therapy, seating/orthotics and contracture/scoliosis surveillance;
speech-language therapy and augmentative/alternative communication;
feeding/swallow evaluation, nutrition support and gastrostomy when aspiration or inadequate growth warrants it;
respiratory monitoring in severely affected males;
hearing aids/cochlear evaluation and ophthalmologic treatment;
sleep, tone, dystonia, constipation and pain management;
special education, social services, palliative-care involvement when appropriate, and genetic counseling.

Suggested NCIT concepts include Supportive Care, Physical Therapy, Occupational Therapy, Speech Therapy, Anticonvulsant Therapy, Gastrostomy, Hearing Aid, and Genetic Counseling. Exact NCIT codes should be resolved against the current NCIT release.

GluN2B restoration rescued synaptic imbalance experimentally, while metabolic work suggests potentially modifiable stress pathways. Neither constitutes evidence for NMDA-targeted medication, supplements or metabolic therapy in patients. Gene replacement is theoretically complicated by developmental timing, cell-type requirements, X-linked mosaicism and CASK’s multiple isoforms/domains. (mori2019deficiencyofcalciumcalmodulindependent pages 1-2, patel2024geneticevidencefor pages 3-4)

13. Prevention

There is no vaccine, lifestyle modification, environmental intervention or prophylactic medication that prevents a de novo CASK variant. Primary reproductive prevention consists of preconception genetic counseling and, when a familial pathogenic variant is known, carrier testing, preimplantation genetic testing, chorionic-villus sampling or amniocentesis. Negative parental blood testing substantially lowers but does not eliminate recurrence risk because gonadal mosaicism is possible.

Secondary prevention means early recognition and intervention: serial infant head measurements, prompt MRI/genomic testing, early EEG for spasms, and early feeding, vision, hearing and developmental services. Tertiary prevention addresses aspiration, malnutrition, uncontrolled seizures, contractures, scoliosis, pressure injury and respiratory complications. Population screening is unsupported because the disorder is ultra-rare, usually de novo, and lacks a validated newborn biomarker.

14. Other species and natural disease

No well-established naturally occurring veterinary MICPCH syndrome, breed predisposition, zoonotic potential or cross-species transmission was identified. CASK orthologs are evolutionarily conserved in vertebrates and invertebrates, supporting conservation of synaptic and hindbrain-related functions. Exact NCBI Taxon and orthologous Gene IDs should be obtained directly from NCBI/Alliance records before database loading. MICPCH is genetic and noninfectious, so transmission is Mendelian/cellular rather than zoonotic.

15. Model organisms

Mouse models include constitutive heterozygous females, neuron-specific conditional knockouts, cerebellum-specific deletions, adult inducible deletions, and knockdown/knockout neurons studied in acute slices. Heterozygous females recapitulate postnatal microcephaly and aspects of systemic growth/metabolic abnormality. Neuron-specific deletion causes seizures and growth retardation, while cerebellar or adult deletion reveals selective granule-cell degeneration and progressive ataxia. (patel2024geneticevidencefor pages 1-3, patel2024geneticevidencefor pages 3-4)

Cellular and slice models show reduced respiration and altered E/I balance, with GluN2B rescue providing a functional intervention experiment. Computational/structural models in 2024 showed that inclusion of vertebrate-specific exons 19–20 changes flexibility of the PDZ–SH3–GuK supradomain and helps explain cerebellar-sparing genotypes. (patel2024geneticevidencefor pages 9-11, mori2019deficiencyofcalciumcalmodulindependent pages 1-2)

Important limitations are perinatal lethality of complete mouse knockout, species differences in brain development, non-equivalence of engineered deletion to human cellular mosaicism, and inability of a single model to reproduce the full visual, auditory, language and cognitive phenotype. Patient-derived iPSC neurons, cerebellar organoids, single-cell profiling and isogenic variant correction would be high-value future systems, but validated MICPCH datasets using these approaches were not identified.

Key recent developments and expert interpretation

The most important recent synthesis is Mori et al., August 2023, which frames CASK disease as domain- and variant-dependent rather than a single uniform syndrome: truncating variants favor MICPCH, whereas hypomorphic missense variants more often cause X-linked intellectual disability with or without nystagmus. DOI/URL: https://doi.org/10.3390/genes14081656. (mori2023diverseclinicalphenotypes pages 2-5)

Patel et al., April 2024, adds genetic and structural evidence that alternative splicing creates distinct CASK functions. Its central conclusion is that loss of CASK disproportionately affects cerebellum, while vertebrate-specific splice isoforms contribute additional forebrain functions. DOI/URL: https://doi.org/10.1136/jmg-2023-109747. (patel2024geneticevidencefor pages 1-3, patel2024geneticevidencefor pages 9-11)

Representative exact abstract statements from retrieved sources are:

“CASK-related disorders are a form of rare X-linked neurological diseases and most of the patients are females.” — Mori et al., 2023. (mori2023diverseclinicalphenotypes pages 2-5)

“Loss of CASK function disproportionately affects the cerebellum.” — Patel et al., 2024. (patel2024geneticevidencefor pages 1-3)

“Both CASK-KO and CASK-KD neurons showed a disruption of the excitatory and inhibitory (E/I) balance.” — Mori et al., 2019. DOI/URL: https://doi.org/10.1038/s41380-018-0338-4. (mori2019deficiencyofcalciumcalmodulindependent pages 1-2)

“We observed a high frequency of patients with a CASK mutation (13/14).” — Burglen et al., March 2012. DOI/URL: https://doi.org/10.1186/1750-1172-7-18. (burglen2012spectrumofpontocerebellar pages 7-9)

PMIDs were not exposed in the retrieved source metadata and therefore are not invented here; DOI URLs provide persistent primary-source links. The most consequential knowledge gaps are unbiased epidemiology, longitudinal adult natural history, variant-level penetrance, patient-reported outcomes, validated biomarkers and controlled therapeutic studies.

References

(mukherjee2022thenonlinearpath pages 2-3): Konark Mukherjee, Leslie E. W. LaConte, and Sarika Srivastava. The non-linear path from gene dysfunction to genetic disease: lessons from the micpch mouse model. Cells, 11:1131, Mar 2022. URL: https://doi.org/10.3390/cells11071131, doi:10.3390/cells11071131. This article has 7 citations.
(mori2023diverseclinicalphenotypes pages 2-5): Takuma Mori, Mengyun Zhou, and Katsuhiko Tabuchi. Diverse clinical phenotypes of cask-related disorders and multiple functional domains of cask protein. Genes, 14:1656, Aug 2023. URL: https://doi.org/10.3390/genes14081656, doi:10.3390/genes14081656. This article has 17 citations.
(patel2024geneticevidencefor pages 1-3): Paras A Patel, Leslie E W LaConte, Chen Liang, Thomas Cecere, Deepa Rajan, Sarika Srivastava, and Konark Mukherjee. Genetic evidence for splicing-dependent structural and functional plasticity in cask protein. Journal of Medical Genetics, 61:759-768, Apr 2024. URL: https://doi.org/10.1136/jmg-2023-109747, doi:10.1136/jmg-2023-109747. This article has 4 citations and is from a domain leading peer-reviewed journal.
(zhang2022adenovo pages 7-10): Ying Zhang, Ya-ling Nie, Y. Mu, Jie Zheng, Xiaowei Xu, Fang Zhang, Jianbo Shu, and Yang Liu. A de novo variant in cask gene causing intellectual disability and brain hypoplasia: a case report and literature review. Italian Journal of Pediatrics, May 2022. URL: https://doi.org/10.1186/s13052-022-01248-z, doi:10.1186/s13052-022-01248-z. This article has 4 citations and is from a peer-reviewed journal.
(hayashi2017comprehensiveinvestigationof pages 2-3): Shin Hayashi, Daniela Tiaki Uehara, Kousuke Tanimoto, Seiji Mizuno, Yasutsugu Chinen, Shinobu Fukumura, Jun-ichi Takanashi, Hitoshi Osaka, Nobuhiko Okamoto, and Johji Inazawa. Comprehensive investigation of cask mutations and other genetic etiologies in 41 patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (micpch). PLOS ONE, 12:e0181791, Aug 2017. URL: https://doi.org/10.1371/journal.pone.0181791, doi:10.1371/journal.pone.0181791. This article has 81 citations and is from a peer-reviewed journal.
(hayashi2017comprehensiveinvestigationof pages 1-2): Shin Hayashi, Daniela Tiaki Uehara, Kousuke Tanimoto, Seiji Mizuno, Yasutsugu Chinen, Shinobu Fukumura, Jun-ichi Takanashi, Hitoshi Osaka, Nobuhiko Okamoto, and Johji Inazawa. Comprehensive investigation of cask mutations and other genetic etiologies in 41 patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (micpch). PLOS ONE, 12:e0181791, Aug 2017. URL: https://doi.org/10.1371/journal.pone.0181791, doi:10.1371/journal.pone.0181791. This article has 81 citations and is from a peer-reviewed journal.
(hayashi2017comprehensiveinvestigationof pages 4-6): Shin Hayashi, Daniela Tiaki Uehara, Kousuke Tanimoto, Seiji Mizuno, Yasutsugu Chinen, Shinobu Fukumura, Jun-ichi Takanashi, Hitoshi Osaka, Nobuhiko Okamoto, and Johji Inazawa. Comprehensive investigation of cask mutations and other genetic etiologies in 41 patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (micpch). PLOS ONE, 12:e0181791, Aug 2017. URL: https://doi.org/10.1371/journal.pone.0181791, doi:10.1371/journal.pone.0181791. This article has 81 citations and is from a peer-reviewed journal.
(burglen2012spectrumofpontocerebellar pages 7-9): Lydie Burglen, Sandra Chantot-Bastaraud, Catherine Garel, Mathieu Milh, Renaud Touraine, Ginevra Zanni, Florence Petit, Alexandra Afenjar, Cyril Goizet, Sabina Barresi, Aurélie Coussement, Christine Ioos, Leila Lazaro, Sylvie Joriot, Isabelle Desguerre, Didier Lacombe, Vincent des Portes, Enrico Bertini, Jean-Pierre Siffroi, Thierry Billette de Villemeur, and Diana Rodriguez. Spectrum of pontocerebellar hypoplasia in 13 girls and boys with cask mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient. Orphanet Journal of Rare Diseases, 7:18-18, Mar 2012. URL: https://doi.org/10.1186/1750-1172-7-18, doi:10.1186/1750-1172-7-18. This article has 126 citations and is from a peer-reviewed journal.
(patel2024geneticevidencefor pages 9-11): Paras A Patel, Leslie E W LaConte, Chen Liang, Thomas Cecere, Deepa Rajan, Sarika Srivastava, and Konark Mukherjee. Genetic evidence for splicing-dependent structural and functional plasticity in cask protein. Journal of Medical Genetics, 61:759-768, Apr 2024. URL: https://doi.org/10.1136/jmg-2023-109747, doi:10.1136/jmg-2023-109747. This article has 4 citations and is from a domain leading peer-reviewed journal.
(mori2019deficiencyofcalciumcalmodulindependent pages 1-2): Takuma Mori, Enas A. Kasem, Emi Suzuki-Kouyama, Xueshan Cao, Xue Li, Taiga Kurihara, Takeshi Uemura, Toru Yanagawa, and Katsuhiko Tabuchi. Deficiency of calcium/calmodulin-dependent serine protein kinase disrupts the excitatory-inhibitory balance of synapses by down-regulating glun2b. Molecular Psychiatry, 24:1079-1092, Jan 2019. URL: https://doi.org/10.1038/s41380-018-0338-4, doi:10.1038/s41380-018-0338-4. This article has 44 citations and is from a highest quality peer-reviewed journal.
(patel2024geneticevidencefor pages 3-4): Paras A Patel, Leslie E W LaConte, Chen Liang, Thomas Cecere, Deepa Rajan, Sarika Srivastava, and Konark Mukherjee. Genetic evidence for splicing-dependent structural and functional plasticity in cask protein. Journal of Medical Genetics, 61:759-768, Apr 2024. URL: https://doi.org/10.1136/jmg-2023-109747, doi:10.1136/jmg-2023-109747. This article has 4 citations and is from a domain leading peer-reviewed journal.
(patel2024geneticevidencefor pages 14-16): Paras A Patel, Leslie E W LaConte, Chen Liang, Thomas Cecere, Deepa Rajan, Sarika Srivastava, and Konark Mukherjee. Genetic evidence for splicing-dependent structural and functional plasticity in cask protein. Journal of Medical Genetics, 61:759-768, Apr 2024. URL: https://doi.org/10.1136/jmg-2023-109747, doi:10.1136/jmg-2023-109747. This article has 4 citations and is from a domain leading peer-reviewed journal.
(patel2024geneticevidencefor pages 11-12): Paras A Patel, Leslie E W LaConte, Chen Liang, Thomas Cecere, Deepa Rajan, Sarika Srivastava, and Konark Mukherjee. Genetic evidence for splicing-dependent structural and functional plasticity in cask protein. Journal of Medical Genetics, 61:759-768, Apr 2024. URL: https://doi.org/10.1136/jmg-2023-109747, doi:10.1136/jmg-2023-109747. This article has 4 citations and is from a domain leading peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

MICPCH syndrome: disease-characteristics research report

Executive summary

1. Disease information

2. Etiology, risk, protection, and gene–environment interaction

3. Phenotypes

4. Genetic and molecular information

5. Environmental information

6. Mechanism and pathophysiology

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

11. Outcome and prognosis

12. Treatment and implementation

13. Prevention

14. Other species and natural disease

15. Model organisms

Key recent developments and expert interpretation

Artifacts